0001104659-22-092128.txt : 20220817 0001104659-22-092128.hdr.sgml : 20220817 20220817141521 ACCESSION NUMBER: 0001104659-22-092128 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220817 DATE AS OF CHANGE: 20220817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Science Strategic Acquisition Corp. Alpha CENTRAL INDEX KEY: 0001830547 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 853594633 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39930 FILM NUMBER: 221173264 BUSINESS ADDRESS: STREET 1: 1447 2ND ST CITY: SANTA MONICA STATE: CA ZIP: 90401 BUSINESS PHONE: 3106214551 MAIL ADDRESS: STREET 1: 1447 2ND ST CITY: SANTA MONICA STATE: CA ZIP: 90401 10-Q 1 ssaau-20220630x10q.htm FORM 10-Q
310500003105000031050000261024730.050.110.170.0877625007762500776250076011680.050.110.170.080001830547--12-312022Q2false310500003105000031050000261024730.050.110.170.0877625007762500776250076011680.050.110.170.08000.330000776250077625003105000007555500170748032463030331050000000776250077625000001830547ssaau:PublicWarrantsMember2022-06-300001830547ssaau:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2022-06-300001830547ssaau:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2022-03-310001830547ssaau:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2021-12-310001830547ssaau:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2021-06-300001830547ssaau:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2021-03-310001830547ssaau:CommonClassaSubjectToRedemptionMember2022-06-300001830547ssaau:CommonClassaSubjectToRedemptionMember2021-12-310001830547ssaau:FounderSharesMemberssaau:SponsorMemberus-gaap:CommonClassBMember2020-10-292020-10-290001830547us-gaap:RetainedEarningsMember2022-06-300001830547us-gaap:RetainedEarningsMember2022-03-3100018305472022-03-310001830547us-gaap:RetainedEarningsMember2021-12-310001830547us-gaap:AdditionalPaidInCapitalMember2021-12-310001830547us-gaap:RetainedEarningsMember2021-06-300001830547us-gaap:RetainedEarningsMember2021-03-3100018305472021-03-310001830547us-gaap:RetainedEarningsMember2020-12-310001830547us-gaap:AdditionalPaidInCapitalMember2020-12-310001830547ssaau:PublicWarrantsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001830547ssaau:PublicAndPrivatePlacementWarrantsMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001830547ssaau:PublicAndPrivatePlacementWarrantsMember2021-12-310001830547us-gaap:IPOMember2021-01-280001830547us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-06-300001830547us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-03-310001830547us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001830547us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-06-300001830547us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-03-310001830547us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001830547ssaau:WorkingCapitalLoanMember2022-06-300001830547ssaau:WorkingCapitalLoanMember2021-12-310001830547ssaau:PromissoryNoteWithRelatedPartyMember2021-01-280001830547us-gaap:RetainedEarningsMember2022-04-012022-06-300001830547us-gaap:RetainedEarningsMember2022-01-012022-03-3100018305472022-01-012022-03-310001830547us-gaap:RetainedEarningsMember2021-04-012021-06-300001830547ssaau:NonRedeemableClassBCommonStockMember2022-04-012022-06-300001830547ssaau:CommonClassaSubjectToRedemptionMember2022-04-012022-06-300001830547ssaau:NonRedeemableClassBCommonStockMember2022-01-012022-06-300001830547ssaau:NonRedeemableClassBCommonStockMember2021-04-012021-06-300001830547ssaau:CommonClassaSubjectToRedemptionMember2021-04-012021-06-300001830547ssaau:NonRedeemableClassBCommonStockMember2021-01-012021-06-300001830547ssaau:CommonClassaSubjectToRedemptionMember2021-01-012021-06-300001830547ssaau:RelatedPartyLoansMember2022-06-300001830547ssaau:RelatedPartyLoansMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputSharePriceMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberssaau:WarrantToBuyOneShareUnadjustedForProbabilityOfDissolutionMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberssaau:WarrantToBuyOneShareAdjustedForProbabilityOfDissolutionMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberssaau:WarrantToBuyOneShareUnadjustedForProbabilityOfDissolutionMember2021-12-310001830547ssaau:PrivatePlacementWarrantsMemberssaau:WarrantToBuyOneShareAdjustedForProbabilityOfDissolutionMember2021-12-3100018305472022-04-012022-06-3000018305472021-04-012021-06-300001830547ssaau:CommonClassaNotSubjectToRedemptionMember2021-12-310001830547us-gaap:CommonClassAMember2022-06-300001830547us-gaap:CommonClassBMember2021-12-310001830547us-gaap:CommonClassAMember2021-12-310001830547ssaau:FounderSharesMemberssaau:SponsorMemberus-gaap:CommonClassBMember2021-01-252021-01-250001830547ssaau:PublicWarrantsMemberus-gaap:CommonClassAMemberus-gaap:IPOMember2021-01-280001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2021-01-280001830547ssaau:PublicWarrantsMemberus-gaap:IPOMember2021-01-2800018305472021-06-3000018305472020-12-310001830547us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001830547us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001830547us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001830547us-gaap:OverAllotmentOptionMember2021-01-282021-01-280001830547us-gaap:IPOMember2021-01-282021-01-280001830547ssaau:CommonClassaSubjectToRedemptionMemberus-gaap:CommonStockMember2021-01-012021-03-310001830547ssaau:CommonClassaSubjectToRedemptionMember2022-01-012022-06-300001830547ssaau:CommonClassaSubjectToRedemptionMember2021-01-012021-12-310001830547us-gaap:RetainedEarningsMember2021-01-012021-03-310001830547ssaau:FounderSharesMemberssaau:SponsorMemberus-gaap:CommonClassBMember2022-01-012022-06-300001830547ssaau:PrivatePlacementWarrantsMember2022-01-012022-06-300001830547ssaau:AdministrativeServicesAgreementMember2022-01-012022-06-300001830547ssaau:PublicWarrantsMemberus-gaap:CommonClassAMember2022-01-012022-06-300001830547ssaau:PublicWarrantsMemberus-gaap:IPOMember2021-01-282021-01-280001830547us-gaap:CommonClassAMemberus-gaap:IPOMember2021-01-282021-01-280001830547srt:ScenarioPreviouslyReportedMember2021-01-012021-06-300001830547ssaau:WorkingCapitalLoanMember2022-05-270001830547ssaau:PromissoryNoteWithRelatedPartyMember2020-10-2900018305472021-01-2800018305472021-01-012021-06-300001830547us-gaap:CommonClassBMember2022-01-012022-06-300001830547us-gaap:CommonClassBMember2022-06-300001830547ssaau:CommonClassaNotSubjectToRedemptionMember2022-06-300001830547ssaau:WorkingCapitalLoansWarrantMemberssaau:WorkingCapitalLoanMember2022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-01-280001830547ssaau:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Memberssaau:PublicWarrantsMember2022-01-012022-06-300001830547ssaau:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Memberssaau:PublicWarrantsMember2022-01-012022-06-300001830547ssaau:PublicWarrantsMember2022-01-012022-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-01-282021-01-280001830547ssaau:AdministrativeServicesAgreementMember2022-06-3000018305472021-01-282021-01-280001830547ssaau:FounderSharesMemberssaau:SponsorMemberus-gaap:CommonClassBMember2021-01-250001830547us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100018305472021-01-012021-03-3100018305472022-06-3000018305472021-12-310001830547us-gaap:CommonClassAMember2022-01-012022-06-300001830547ssaau:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember2022-01-012022-06-300001830547ssaau:UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember2022-01-012022-06-300001830547us-gaap:CommonClassBMember2022-08-170001830547us-gaap:CommonClassAMember2022-08-1700018305472022-01-012022-06-30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesssaau:Dssaau:itemssaau:Vote

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39930

Science Strategic Acquisition Corp. Alpha

(Exact name of registrant as specified in its charter)

Delaware

    

85-3594633

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer Identification No.) 

1447 2nd Street

Santa Monica, CA 90401

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (310) 393-3024

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Units, each consisting of one share of Class A
common stock, $0.0001 par value, and one-third of
one redeemable warrant

 

SSAAU

 

The Nasdaq Stock Market LLC

Class A common stock

 

SSAA

 

The Nasdaq Stock Market LLC

Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50

 

SSAAW

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

    

Accelerated filer

 Non-accelerated filer

Smaller reporting company

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

As of August 17, 2022, the Registrant had 31,050,000 shares of Class A common stock, par value $0.0001 per share, and 7,762,500 shares of Class B common stock, par value $0.0001 per share, issued and outstanding.

SCIENCE STRATEGIC ACQUISITION CORP. ALPHA

Table of Contents

    

     

Page

PART I.

FINANCIAL INFORMATION

1

Item 1.

Financial Statements

1

Condensed Balance Sheets as of June 30, 2022 (unaudited) and December 31, 2021 (audited)

1

Condensed Statements of Operations for the three and six months ended June 30, 2022 and June 30, 2021 (unaudited)

2

Condensed Statements of Changes in Stockholders’ Deficit for the three and six months ended June 30, 2022 and June 30, 2021 (unaudited)

3

Condensed Statements of Cash Flows for the six months ended June 30, 2022 and June 30, 2021 (unaudited)

4

Notes to Interim Condensed Financial Statements (unaudited)

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

23

Item 4.

Controls and Procedures

23

PART II.

OTHER INFORMATION

25

Item 1.

Legal Proceedings

25

Item 1A.

Risk Factors

25

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

25

Item 3.

Defaults Upon Senior Securities

26

Item 4.

Mine Safety Disclosures

26

Item 5.

Other Information

26

Item 6.

Exhibits

27

Signatures

28

i

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Science Strategic Acquisition Corp. Alpha

Condensed Balance Sheets

June 30, 

December 31, 

2022

2021

    

(unaudited)

    

(audited)

ASSETS

Current assets

Cash

$

511,761

$

346,319

Prepaid expenses - current

239,075

337,104

Total Current Assets

750,836

683,423

Noncurrent assets

Marketable securities held in Trust Account

310,780,579

310,544,829

Prepaid expenses - noncurrent

27,689

Total Noncurrent Assets

310,780,579

310,572,518

TOTAL ASSETS

$

311,531,415

$

311,255,941

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current liabilities

Accrued offering costs

$

$

70,000

Related party payables

19,244

250,000

Working capital loan payable

750,000

Accrued expenses

1,565,164

1,315,635

Total Current Liabilities

2,334,408

1,635,635

Noncurrent liabilities

Warrant liability

1,424,100

8,544,600

Deferred underwriting fee payable

10,867,500

10,867,500

Total Noncurrent Liabilities

12,291,600

19,412,100

Total Liabilities

14,626,008

21,047,735

Commitments and Contingencies (Note 7)

Class A Common stock subject to possible redemption, 31,050,000 shares at redemption value as of June 30, 2022 and December 31, 2021

310,500,000

310,500,000

Stockholders’ Deficit

Preferred stock, $0.0001 par value; 1,000,000 authorized; none issued and outstanding

Class A Common stock, $0.0001 par value; 400,000,000 shares authorized; none issued and outstanding (excluding 31,050,000 shares subject to possible redemption)

Class B Common stock, $0.0001 par value; 40,000,000 shares authorized; 7,762,500 shares issued and outstanding

776

776

Additional paid-in capital

Accumulated deficit

(13,595,369)

(20,292,570)

Total Stockholders’ Deficit

(13,594,593)

(20,291,794)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

$

311,531,415

$

311,255,941

See accompanying notes to interim condensed financial statements (unaudited).

1

Science Strategic Acquisition Corp. Alpha

Condensed Statements of Operations

(unaudited)

    

For the

    

For the

Three Months Ended

Six Months Ended

June 30,

June 30, 

    

2022

    

2021

2022

    

2021

Operating expenses

$

341,179

$

211,844

$

659,049

$

729,474

Loss from operations

(341,179)

(211,844)

(659,049)

(729,474)

Other income (expense):

Unrealized gain on marketable securities held in Trust Account

231,412

6,774

235,750

34,744

Change in fair value of warrant liability

2,057,033

(3,986,035)

7,120,500

(1,929,002)

Total other income (expense)

2,288,445

(3,979,261)

7,356,250

(1,894,258)

Net income (loss)

$

1,947,266

$

(4,191,105)

$

6,697,201

$

(2,623,732)

Basic and diluted weighted average shares outstanding of redeemable Class A common stock

31,050,000

31,050,000

31,050,000

26,102,473

Basic and diluted net income (loss) per share, redeemable Class A common stock

$

0.05

$

(0.11)

$

0.17

$

(0.08)

Basic and diluted weighted average shares outstanding of nonredeemable Class B common stock

7,762,500

7,762,500

7,762,500

7,601,168

Basic and diluted net income (loss) per share, nonredeemable Class B common stock

$

0.05

$

(0.11)

$

0.17

$

(0.08)

See accompanying notes to interim condensed financial statements (unaudited).

2

Science Strategic Acquisition Corp. Alpha

Condensed Statements of Changes in Stockholders’ Deficit

(unaudited)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022

Class A Common

Stock Subject to

Class B

Additional

Total

Possible Redemption

Common Stock

Paid in

Accumulated

Stockholders’

    

Shares

    

Amount

  

  

Shares

    

Amount

    

Capital

    

Deficit

    

Deficit

Balance — December 31, 2021 (audited)

31,050,000

$

310,500,000

7,762,500

$

776

$

$

(20,292,570)

$

(20,291,794)

Net income

4,749,935

4,749,935

Balance — March 31, 2022 (unaudited)

31,050,000

310,500,000

7,762,500

776

(15,542,635)

(15,541,859)

Net income

1,947,266

1,947,266

Balance — June 30, 2022 (unaudited)

 

31,050,000

$

310,500,000

7,762,500

$

776

$

$

(13,595,369)

$

(13,594,593)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021

Class A Common

Stock Subject to

Class B

Additional

Total

Possible Redemption

Common Stock

Paid in

Accumulated

Stockholders’

    

Shares

    

Amount

  

  

Shares

    

Amount

    

Capital

    

Deficit

    

Deficit

Balance — December 31, 2020 (audited)

$

7,762,500

$

776

$

24,224

$

(5,000)

$

20,000

Issuance of 31,050,000 Units

 

31,050,000

285,869,697

 

 

 

Proceeds received in excess of fair value of public warrants

4,159,734

4,159,734

Remeasurement of Class A common stock subject to possible redemption

24,630,303

(4,183,958)

(20,446,345)

(24,630,303)

Net income

1,567,374

1,567,374

Balance — March 31, 2021 (unaudited)

31,050,000

$

310,500,000

7,762,500

$

776

(18,883,971)

(18,883,195)

Net loss

(4,191,105)

(4,191,105)

Balance — June 30, 2021 (unaudited)

31,050,000

$

310,500,000

7,762,500

$

776

$

$

(23,075,076)

$

(23,074,300)

See accompanying notes to interim condensed financial statements (unaudited).

3

Science Strategic Acquisition Corp. Alpha

Condensed Statements of Cash Flows

(unaudited)

For the Six Months Ended

June 30,

    

2022

    

2021

Cash Flows used in Operating Activities:

Net income (loss)

$

6,697,201

$

(2,623,732)

Adjustments to reconcile net income (loss) to net cash used in operating activities:

Unrealized gain on marketable securities held in Trust Account

(235,750)

(34,744)

Change in fair value of warrant liability

(7,120,500)

1,929,002

Warrant issuance costs

420,743

Changes in operating assets and liabilities:

Prepaid expenses, net of amortization

125,718

(566,520)

Related party payable

(230,756)

Accrued offering costs

(70,000)

Accrued expenses

249,529

2,018

Net cash used in operating activities

(584,558)

(873,233)

Cash Flows from Investing Activities:

Investment of cash in Trust Account

(310,500,000)

Net cash used in investing activities

(310,500,000)

Cash Flows from Financing Activities:

Proceeds from sale of Units, net of underwriting discounts paid

304,290,000

Proceeds from the sale of Private Placements Warrants

8,210,000

Proceeds from promissory note — related party

300,000

Repayment of promissory note — related party

(300,000)

Proceeds from working capital loan

750,000

Payment of offering costs

(278,045)

Net cash provided by financing activities

750,000

312,221,955

Net Change in Cash

165,442

848,722

Cash — Beginning of period

346,319

20,000

Cash — End of period

$

511,761

$

868,722

Non-Cash investing and financing activities:

Initial classification of Class A common stock subject to possible redemption

$

$

285,869,697

Remeasurement of Class A common stock subject to possible redemption

$

$

24,630,303

Initial fair value of warrant liability

$

$

11,605,766

Deferred offering costs included in accrued offering costs

$

$

135,000

See accompanying notes to interim condensed financial statements (unaudited).

4

Science Strategic Acquisition Corp. Alpha

Notes to Interim Condensed Financial Statements

(unaudited)

NOTE 1. ORGANIZATION AND PLANS OF BUSINESS OPERATIONS

Organization and General

Science Strategic Acquisition Corp. Alpha (the “Company”) was incorporated in Delaware on October 22, 2020. The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”). The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

Sponsor and Initial Financing

As of June 30, 2022, the Company had not commenced any operations. All activity through June 30, 2022 relates to the Company’s formation, the initial public offering (the “Initial Public Offering”), which is described below, and identifying a target for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering, and non-operating income or expenses from the change in fair value of warrant liability.

The registration statements for the Initial Public Offering were declared effective on January 25, 2021. On January 28, 2021, the Company consummated the Initial Public Offering of 31,050,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), which includes the exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at $10.00 per Unit, generating gross proceeds of $310,500,000, which is described in Note 4.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,473,333 warrants (each, a “Private Placement Warrant” and, collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to SSAC Alpha Sponsor, LLC (the “Sponsor”), generating gross proceeds of $8,210,000, which is described in Note 5.

Transaction costs amounted to $17,495,500, consisting of $6,210,000 of underwriting fees, $10,867,500 of deferred underwriting fees and $418,000 of other offering costs. In addition, cash of approximately $2,300,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.

The Trust Account

Following the closing of the Initial Public Offering on January 28, 2021, an amount of $310,500,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”). The funds in the Trust Account will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended. The Company will not be permitted to withdraw any of the principal or interest held in the Trust Account except for the withdrawal of interest to pay taxes, if any. The funds held in the Trust Account will not otherwise be released from the trust account until the earliest of: (1) the Company’s completion of a Business Combination; (2) the redemption of any Public Shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete a Business Combination on or before January 28, 2023 or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity; and (3) the redemption of the Company’s Public Shares if the Company has not completed a Business Combination on or before January 28, 2023, subject to applicable law. Based on current interest rates, the Company expects that interest earned on the Trust Account will be sufficient to pay taxes.

5

Business Combination

The Company’s management has broad discretion with respect to the specific application of the net proceeds from the Initial Public Offering, although substantially all of the net proceeds from the Initial Public Offering are intended to be generally applied toward consummating a Business Combination with (or acquisition of) a Target Business. As used herein, “Target Business” means one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the Trust Account (excluding taxes payable on the interest earned on the Trust Account) at the time of the signing of a definitive agreement in connection with a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully effect a Business Combination.

The Company will provide its public stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination, either (i) in connection with a stockholder meeting called to approve such Business Combination or (ii) by means of a tender offer. The public stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account, calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to the public stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 7). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.

The decision as to whether the Company will seek stockholder approval of a Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, in its sole discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval unless a vote is required by law or stock exchange listing requirements. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the shares of common stock voted are voted in favor of a Business Combination. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 upon consummation of a Business Combination. In such case, the Company would not proceed with the redemption of its Public Shares and the related Business Combination, and instead may search for an alternate Business Combination.

The Company will have until January 28, 2023 to complete its initial Business Combination. If the Company does not complete a Business Combination by such date (or such longer period as provided in an amendment to the Company’s amended and restated certificate of incorporation approved by its stockholders (an “Extension Period”)), it shall (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. The initial stockholders have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares (as defined in Note 6) if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. However, if the initial stockholders acquire Public Shares, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period.

6

The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to have all third parties, including, but not limited to, all vendors, service providers (other than its independent registered public accounting firm), prospective target businesses and other entities with which the Company does business execute agreements with the Company waiving any right, title, interest or claims of any kind in or to any monies held in the Trust Account.

Liquidity, Capital Resources and Going Concern

As of June 30, 2022, the Company had $511,761 in cash held outside of the Trust Account and a working capital deficit of $1,483,572.

The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor to cover certain offering costs on the Company’s behalf in exchange for the issuance of Founder Shares (as discussed in Note 6), and a loan from the Sponsor of $300,000 under the Promissory Note (as discussed in Note 6). The Company repaid the Promissory Note in full on February 2, 2021. Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the private placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Sponsor may provide up to $750,000 to the Company as a working capital loan (the “Working Capital Loan”) (as discussed in Note 6). As of June 30, 2022 and December 31, 2021, there was $750,000 and $0 outstanding under the Working Capital Loan, respectively. In order to fund working capital deficiencies or finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s directors and officers may, but are not obligated to, loan the Company additional funds (“Additional Working Capital Loans”) as may be required.

The Company has incurred and expects to incur significant costs in pursuit of its financing and acquisition plans. Management believes that the Company has access to funds from the Sponsor that are sufficient to fund the working capital needs of the Company until the consummation of an initial Business Combination or for a minimum of one year from the date of issuance of these financial statements. However, in connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Company’s cash flow deficit and the liquidation date of January 28, 2023 being within twelve months from the issuance of these financial statements raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. There is no assurance that the Company’s plans to consummate a Business Combination or raise additional funds will be successful. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2. REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

In connection with the preparation of the Company's financial statements as of June 30, 2022, management identified an error made in its historical financial statements where, warrant issuance costs were incorrectly included within the financing activities section of the Statement of Cash Flows as of June 30, 2021. The Company revised the Condensed Statements of Cash Flows by reclassifying warrant issuance costs from financing activities to operating activities for the six months ended June 30, 2021.

7

The impact of the revision on the Company’s Condensed Statements of Cash Flows is reflected in the following table:

    

As Previously Reported

    

As Revised

For the Six Months Ended

For the Six Months Ended

June 30, 2021

June 30, 2021

Cash Flows Used in Operating Activities:

 

  

 

  

Warrant issuance costs

 

 

420,743

Net cash used in operating activities

 

(1,293,976)

 

(873,233)

Cash Flows From Financing Activities:

 

  

 

  

Proceeds from sale of Units, net of underwriting discounts paid

 

304,710,744

 

304,290,000

Net cash provided by financing activities

 

312,642,698

 

312,221,955

There is no impact to the reported amounts for total assets, total liabilities, or net income.

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on April 12, 2022, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2021 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

8

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2022 and December 31, 2021.

Offering Costs

Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.

Marketable Securities Held in Trust Account

At June 30, 2022, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities. Through June 30, 2022, the Company has not withdrawn any monies from the Trust Account.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The provision for income taxes was deemed to be de minimis for the three and six months ended June 30, 2022.

Net Income (Loss) per Share

Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period in compliance with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings per Share.” The remeasurement associated with the redeemable Class A common stock is excluded from net income (loss) per share as the redemption value approximates fair value. The Company has not considered the effect of the warrants sold in the Initial Public Offering

9

and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted net income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods presented.

The Company’s condensed statement of operations includes a presentation of net income (loss) per share of Class A common stock subject to possible redemption and non-redeemable Class B common stock and allocates the net income (loss) into the two classes of stock in calculating net income (loss). Net income (loss) per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class A common stock subject to possible redemption outstanding. Net income (loss) per share, basic and diluted, for Class B non-redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class B non-redeemable common stock outstanding for the period. As of June 30, 2022 and June 30, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercisable or converted to shares of common stock and then share in the earnings of the Company.

The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts):

For the Three Months Ended

For the Six Months Ended

June 30,

June 30, 

2022

2021

2022

2021

    

(unaudited)

(unaudited)

    

(unaudited)

    

(unaudited)

Class A common stock subject to possible redemption

 

  

 

  

Numerator: Net income (loss) attributable to Class A Common Stock subject to possible redemption

 

  

 

  

Net income (loss)

$

1,557,813

$

(3,352,884)

$

5,357,761

$

(2,032,003)

Net income (loss) attributable to Class A common stock subject to possible redemption

$

1,557,813

$

(3,352,884)

$

5,357,761

$

(2,032,003)

Denominator: Weighted average Class A common stock subject to possible redemption

Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption

31,050,000

31,050,000

31,050,000

26,102,473

Basic and diluted net income (loss) per share, Class A Common Stock subject to possible redemption

$

0.05

$

(0.11)

$

0.17

$

(0.08)

Non-Redeemable Class B Common Stock

Numerator: Net income (loss) attributable to Class B common stock

Net income (loss)

$

389,453

$

(838,221)

1,339,440

$

(591,729)

Non-redeemable net income (loss)

$

389,453

$

(838,221)

$

1,339,440

$

(591,729)

Denominator: Weighted average shares of non-redeemable Class B common stock

Basic and diluted weighted average shares outstanding, non-redeemable Class B common stock

7,762,500

7,762,500

7,762,500

7,601,168

Basic and diluted net income (loss) per share, non-redeemable Class B common stock

$

0.05

$

(0.11)

0.17

$

(0.08)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.

10

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Warrants Exercisable for Class A Common Stock

The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, “Derivatives and Hedging” (“ASC 815”). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

Working Capital Loan Payable

The Company accounted for the Working Capital Loan payable in accordance with ASC 470, “Debt”. The Working Capital Loan payable is recorded at amortized cost. The conversion option feature had a fair value of $0 as of on June 1, 2022, the date of initial measurement. As such, there is no debt discount recorded as there are no proceeds to allocate to the conversion option feature.

Class A Common Stock Subject to Possible Redemption

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheets.

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Such changes are reflected in additional paid-in capital to the extent available, or in the absence of additional capital, in accumulated deficit.

11

At June 30, 2022 and December 31, 2021, the Class A common stock subject to possible redemption reflected in the condensed balance sheets is reconciled in the following table:

Gross proceeds from initial public offering

    

$

310,500,000

Less:

 

  

Proceeds allocated to public warrants

 

(7,555,500)

Offering costs allocated to Class A common stock subject to possible redemption

 

(17,074,803)

Add:

 

  

Remeasurement on Class A common stock subject to possible redemption amount

 

24,630,303

Class A common stock subject to possible redemption

$

310,500,000

Recent Accounting Pronouncements

In August 2020, FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.

NOTE 4. INITIAL PUBLIC OFFERING

On January 28, 2021, pursuant to the Initial Public Offering, the Company sold 31,050,000 Units, which includes the full exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and one-third of one redeemable warrant (each whole warrant, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment (see Note 9).

NOTE 5. PRIVATE PLACEMENT

Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 5,473,333 Private Placement Warrants, at a price of $1.50 per Private Placement Warrant, for an aggregate purchase price of $8,210,000 in a private placement. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share. $6,210,000 of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination by January 28, 2023 or during any Extension Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.

NOTE 6. RELATED PARTY TRANSACTIONS

Founder Shares

On October 29, 2020, the Sponsor purchased 6,468,750 shares of Class B common stock for an aggregate purchase price of $25,000. On January 25, 2021, the Company effected a stock dividend of 1,293,750 shares of Class B common stock to holders of Class B common stock on a pro rata basis based on their holdings, resulting in the Company’s initial stockholders holding an aggregate of 7,762,500 shares of Class B common stock (see Note 8). All share and per-share amounts have been retroactively restated to reflect the stock dividend.

12

The initial stockholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Class B common stock or Class A common stock received upon conversion thereof (together, “Founder Shares”) until the earlier of: (A) one year after the completion of a Business Combination; and (B) subsequent to a Business Combination (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of common stock for cash, securities or other property.

Promissory Note — Related Party

On October 29, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Promissory Note”). The Promissory Note was non-interest bearing and payable on the earlier of December 31, 2021 or the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $300,000 remained outstanding at the closing of the Initial Public Offering on January 28, 2021. On February 2, 2021, the Company repaid the Promissory Note in full.

Administrative Services Agreement

The Company agreed, commencing on the date that securities of the Company were first listed on the Nasdaq Capital Market through the earlier of the Company’s consummation of a Business Combination or its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, administrative and support services. The Company and the affiliate of the Sponsor canceled the Administrative Services Agreement effective March 31, 2022 as the affiliate of the Sponsor agreed to waive the monthly payments. No amounts have been accrued or paid for the period from the commencement date through June 30, 2022.

Related Party Payables

The Company owed $19,244 and $250,000 as of June 30, 2022 and December 31, 2021, respectively, to a related party for certain costs paid by an affiliate of the Sponsor.

Working Capital Loan

On May 27, 2022, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Sponsor may provide up to $750,000 to the Company as a working capital loan. The Working Capital Loan does not bear interest and is repayable in full on the earlier of (i) the consummation of the Company’s initial Business Combination or (ii) end of the Business Combination period. Upon the consummation of a Business Combination, the Sponsor shall have the option, but not the obligation, to convert the principal balance of the Working Capital Loan, in whole or in part, into warrants at a price of $1.50 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loan but no proceeds held in the Trust Account would be used to repay the Working Capital Loan. The Working Capital Loan is subject to customary events of default, the occurrence of which automatically trigger the unpaid principal balance of the Working Capital Loan and all other sums payable with regard to the Working Capital Loan becoming immediately due and payable. As of June 30, 2022 and December 31, 2021, there was $750,000 and $0 outstanding under the Working Capital Loan, respectively.

13

NOTE 7. COMMITMENTS AND CONTINGENCIES

Registration Rights

The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued on conversion of the Working Capital Loan or Additional Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loan or Additional Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement signed in conjunction with the Initial Public Offering requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Company’s Class A common stock). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,867,500 in the aggregate. The deferred fee will be waived by the underwriters in the event that the Company does not complete a Business Combination by January 28, 2023, subject to the terms of the underwriting agreement.

NOTE 8. STOCKHOLDERS’ DEFICIT

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The board of directors is able to, without stockholder approval, issue shares of preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the common stock and could have anti-takeover effects. At June 30, 2022 and December 31, 2021, there were no shares of preferred stock issued or outstanding.

Class A Common Stock — The Company is authorized to issue 400,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were no shares of Class A common stock issued and outstanding, excluding 31,050,000 shares of Class A common stock subject to possible redemption, which are presented as temporary equity.

Class B Common Stock — The Company is authorized to issue 40,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were 7,762,500 shares of Class B common stock issued and outstanding.

Holders of Class B common stock have the right to elect all of the Company’s directors prior to a Business Combination. Holders of Class A common stock and Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders except as required by law.

The Class B common stock will automatically convert into Class A common stock at the time of the completion of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which Founder Shares will convert into Class A common stock will be adjusted (subject to waiver by holders of a majority of the Class B common stock) so that the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of the common stock issued and outstanding upon completion of the Initial Public Offering plus the number of shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination, excluding any shares of Class A common stock or equity-linked securities issued, or to be issued, to any seller in a Business Combination.

14

NOTE 9. WARRANTS

Warrants— Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months after the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement governing the Warrants (the “Warrant Agreement”). The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However except as described below, the warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination by January 28, 2023 or during an Extension Period and the Company liquidates the funds held in the Trust Account, holders of the warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution form the Company’s assets held outside the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.

In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the completion of the Company’s initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of shares of the Company’s Class A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummate a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00” and “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.

The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration or a valid exemption from registration is available. No Public Warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their Public Warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.

The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement registering the issuance, under the Securities Act, of the Class A common stock issuable upon exercise of the Public Warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the Warrant Agreement. Notwithstanding the above, if the Class A common stock is, at the time of any exercise of a Public Warrant, not listed on a national securities exchange such that they do not satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their Public Warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

15

Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:

in whole and not in part;
at a price of $0.01 per Public Warrant;
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
if, and only if, the last reported sale price of shares of the Class A common stock for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant).

Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:

in whole and not in part;
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the “fair market value” of the Class A common stock;
if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted); and
if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants.

If and when the Public Warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

The Private Placement Warrants are identical to the Public Warrants underlying the Units that were sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and are exercisable by such holders on the same basis as the Public Warrants.

The Warrants are not considered to be indexed to the Company’s stock price. In accordance with ASC 815, the warrants were classified as a liability in the total amount of $11.6 million at January 28, 2021. In addition, the warrants must be valued every reporting period and adjusted to market value with the increase or decrease being adjusted through earnings. As of June 30, 2022 and December 31, 2021, the fair value of the warrant liability was $1,424,100 and $8,544,600, respectively.

NOTE 10. FAIR VALUE MEASUREMENTS

The following table presents fair value information at June 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. The Company’s warrant liability is based on a valuation model utilizing management’s judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair value of the Private Placement Warrants liability is classified within Level 3 of the fair value hierarchy. There was no transfer of fair value measurements between levels of the fair value hierarchy for the three and six months ended June 30, 2022.

16

The following tables set forth by level within the fair value hierarchy the Company’s assets and liabilities that were accounted for at fair value on a recurring basis:

    

June 30, 2022 (unaudited)

    

(Level 1)

    

(Level 2)

    

(Level 3)

Assets

 

  

 

  

 

  

Cash and marketable securities held in Trust Account

$

310,780,579

$

$

Liabilities

 

 

  

 

  

Public Warrants

$

931,500

$

$

Private Placement Warrants

$

$

$

492,600

    

December 31, 2021

    

(Level 1)

    

(Level 2)

    

(Level 3)

Assets

  

  

  

Cash and marketable securities held in Trust Account

$

310,544,829

$

$

Liabilities

 

 

  

 

  

Public Warrants

$

5,589,000

$

$

Private Placement Warrants

$

$

$

2,955,600

Measurement

At June 30, 2022, the Company’s warrant liability was valued at $1,424,100. Under the guidance in Subtopic 815-40, the Public Warrants and the Private Placement Warrants do not meet the criteria for equity treatment. As such, the Public Warrants and the Private Placement Warrants must be recorded as a liability on the balance sheet at fair value. This valuation is subject to re-measurement at each balance sheet date. With each re-measurement, the valuations will be adjusted to fair value, with the change in fair value recognized in the Company’s condensed statement of operations.

The Warrants were initially valued using a Monte Carlo simulation model, with the observable assumptions as provided in the table below. Significant increases in the expected stock prices and expected liquidity would result in a significantly higher fair value measurement. Significant increases in either the probability or severity of default of the host instrument would result in a significantly lower fair value measurement. The measurement of the Public Warrants after the detachment of the Public Warrants from the Units is classified as Level 1 due to the use of an observable market quote in an active market. For periods subsequent to the detachment of the Public Warrants from the Units, the closing price of the Public Warrants was used as the fair value for the Public Warrants as of each relevant date. The Private Placement Warrants are valued using a Monte Carlo simulation model at each reporting period.

The key inputs into the Monte Carlo simulation model formula utilized to value the Private Placement Warrants were as follows at June 30, 2022 and December 31, 2021:

June 30, 

December 31, 

Input

    

2022

    

2021

Common stock price

$

9.81

$

9.75

Exercise price

$

11.50

$

11.50

Risk-free rate of interest

 

2.97

%

1.34

%

Volatility

 

6.31

%

9.10

%

Term

 

5.51

6.00

Warrant to buy one share (unadjusted for the probability of dissolution)

$

0.60

$

0.54

Warrant to buy one share (adjusted for the probability of dissolution)

$

0.09

$

0.54

Dividend yield

0.00

%

0.00

%

NOTE 11. INCOME TAX

During the three and six months ended June 30, 2022, the Company did not record any income tax benefits for the net operating losses incurred due to the uncertainty of realizing a benefit from those items. Taxes generated on the interest income on amounts held in the Trust Account are offset by the net operating losses and valuation allowance.

17

The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company considered the history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies, and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As such, the Company recorded a full valuation allowance against net deferred tax assets as of June 30, 2022 and December 31, 2021.

NOTE 12. SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.

18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this quarterly report on Form 10-Q (the “Quarterly Report”) to “we,” “our,” “us,” and “Company” refer to Science Strategic Acquisition Corp. Alpha. References to our “management” or our “management team” refer to our officers and directors, and references to our “Sponsor” refer to SSAC Alpha Sponsor, LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations thereof and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of this Quarterly Report and the Risk Factors section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission (the “SEC”) on April 12, 2022. Except as expressly required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company incorporated as a Delaware corporation on October 22, 2020 for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to as a Business Combination. We completed our initial public offering (our “IPO”) on January 28, 2021, which is described below under “—Liquidity and Capital Resources.”

While we may pursue a business combination target in any industry, we currently intend to focus our search for a target business in the direct-to-consumer brands, direct-to-consumer-services and mobile and social entertainment sectors. Since completing our IPO, we have reviewed, and continue to review, a number of opportunities to enter into a Business Combination with an operating business, but we are not able to determine at this time whether we will complete a Business Combination with any of the target businesses that we have reviewed or with any other target business. We intend to effectuate a Business Combination using cash from the proceeds of our IPO and the sale of the Private Placement Warrants (as defined below), our capital stock, debt, or a combination of cash, stock and debt.

Results of Operations

For the three months ended June 30, 2022, we had net income of $2.0 million consisting of approximately $2.1 million gain on the change in fair value of warrant liability and $0.2 million unrealized gain on marketable securities held in the Trust Account, partially offset by approximately $0.3 million in general and administrative expenses. For the three months ended June 30, 2021, we had net loss of $4.2 million consisting of approximately $4.0 million loss on the change in fair value of warrant liability and $0.2 million of general and administrative expenses.

For the six months ended June 30, 2022, we had net income of $6.7 million consisting of approximately $7.1 million gain on the change in fair value of warrant liability and $0.2 million unrealized gain on marketable securities held in the Trust Account, partially offset by approximately $0.7 million in general and administrative expenses. For the six months ended June 30, 2021, we had net loss of $2.6 million consisting of approximately $1.9 million loss on the change in fair value of warrant liability and $0.7 million of general and administrative expenses.

19

Our business activities during the three and six months ended June 30, 2022 consisted primarily of identifying and evaluating prospective acquisition candidates for a Business Combination. We believe that we have access to additional funds from the Sponsor that, together with cash held outside the Trust Account (as defined below), are sufficient to effect a Business Combination with an operating business by January 28, 2023. Additionally, we have raised $750,000 of additional cash through the Working Capital Loan (as defined below). However, if our estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination. There is no assurance that our plans to consummate a Business Combination or raise additional funds will be successful.

We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held in the Trust Account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence and other expenses in connection with searching for a target and completing a Business Combination.

Liquidity and Capital Resources

As of June 30, 2022, we had approximately $0.5 million in our operating bank account, and working capital deficit of approximately $1.4 million.

Our liquidity needs up to the completion of our IPO on January 28, 2021 had been satisfied through a payment from our Sponsor of $25,000 for 7,762,500 shares (the “Founder Shares”) of our Class B common stock and a loan of $300,000 from our Sponsor, which was repaid on February 2, 2021.

On January 28, 2021, we consummated our IPO of 31,050,000 units (the “Units”), including the issuance of 4,050,000 Units as a result of the underwriter’s full exercise of its over-allotment option. Each Unit consists of one share of our Class A common stock and one-third of one warrant of the Company, with each whole warrant entitling the holder thereof to purchase one whole share of Class A common stock at a price of $11.50 per share, subject to certain adjustments. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $310,500,000. Simultaneously with the closing of our IPO, we completed the private sale of an aggregate of 5,473,333 private placement warrants (the “Private Placement Warrants”) to our Sponsor at a purchase price of $1.50 per Private Placement Warrant, generating gross proceeds to us of $8,210,000.

A total of $310,500,000, comprised of the net proceeds of the IPO and the sale of the Private Placement Warrants, was placed in a U.S.-based trust account (the “Trust Account”) at JP Morgan Chase Bank, N.A., maintained by Continental Stock Transfer & Trust Company, acting as trustee. Transaction costs for the IPO and the sale of the Private Placement Warrants amounted to $17,495,500 consisting of $6,210,000 of underwriting fees, $10,867,500 of deferred underwriting fees and $418,000 of other offering costs. In addition, as of June 30, 2022, approximately $0.5 million of cash was held outside of the Trust Account and is available for working capital purposes.

As of June 30, 2022, we had marketable securities held in the Trust Account of $310,780,579 consisting of U.S. Treasury Bills with a maturity of 180 days or less. Interest income on the balance in the Trust Account may be used by us to pay taxes.

For the six months ended June 30, 2022, cash used in operating activities was $0.6 million. Net income of $6.7 million was affected by a gain on the change in fair value of our warrant liability of $7.1 million and unrealized gain on marketable securities held in the Trust Account of $0.2 million. Changes in operating assets and liabilities provided $0.1 million of cash for operating activities.

For the six months ended June 30, 2021, cash used in operating activities was $0.9 million. Net loss of $2.6 million was affected by a loss on the change in fair value of our warrant liability of $1.9 million, and unrealized gain on marketable securities held in the Trust Account of less than $0.1 million, and a non-cash warrant issuance cost of $0.4 million. Changes in operating assets and liabilities used $0.6 million of cash for operating activities.

We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account, which interest shall be net of taxes payable and excluding deferred underwriting commissions, to complete our Business Combination. We may make permitted withdrawals from the Trust Account to pay our taxes, including franchise taxes and income taxes. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Business Combination,

20

the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

We intend to use funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a business combination, and to pay taxes to the extent the interest earned on the Trust Account is not sufficient to pay our taxes.

On May 27, 2022, we issued an unsecured promissory note to our Sponsor, pursuant to which our Sponsor may provide up to $750,000 to us as a working capital loan (the “Working Capital Loan”). The Working Capital Loan does not bear interest and is repayable in full on the earlier of (i) the consummation of the Company’s initial Business Combination or (ii) end of the Business Combination period. Upon the consummation of a Business Combination, our Sponsor shall have the option, but not the obligation, to convert the principal balance of the Working Capital Loan, in whole or in part, into warrants at a price of $1.50 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, we may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loan but no proceeds held in the Trust Account would be used to repay the Working Capital Loan. The Working Capital Loan is subject to customary events of default, the occurrence of which automatically trigger the unpaid principal balance of the Working Capital Loan and all other sums payable with regard to the Working Capital Loan becoming immediately due and payable. As of June 30, 2022 and the date of this Quarterly Report, there was $750,000 outstanding under the Working Capital Loan.

In order to fund working capital deficiencies or finance transaction costs in connection with an intended Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our directors and officers may, but are not obligated to, loan us additional funds as may be required. Similar to the Working Capital Loan described above, up to $750,000 of such loans may be convertible into warrants at a price of $1.50 per warrant at the option of the lender and such warrants would be identical to the Private Placement Warrants issued to our Sponsor.

The Company has incurred and expects to incur significant costs in pursuit of its financing and acquisition plans. Management believes that the Company has access to funds from the Sponsor that are sufficient to fund the working capital needs of the Company until the consummation of an initial Business Combination or for a minimum of one year from the date of issuance of the financial statements accompanying this Quarterly Report. However, in connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Company’s cash flow deficit and the deadline to consummate an initial Business Combination being within twelve months from the issuance of the financial statements accompanying this Quarterly Report raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements accompanying this Quarterly Report are issued. There is no assurance that the Company’s plans to consummate a Business Combination or raise additional funds will be successful. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Contractual Obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than the Working Capital Loan and as described below.

We had an agreement to pay an affiliate of our Sponsor a monthly fee of $10,000 for office space and administrative and support services provided to the Company. The Company and the affiliate of our Sponsor canceled the agreement effective March 31, 2022 as the affiliate of our Sponsor agreed to waive the monthly payments. No amounts have been accrued or paid for the period from the commencement date through June 30, 2022.

The underwriter of the IPO is entitled to a deferred discount of $0.35 per Unit, or $10,867,500 in the aggregate. The deferred discount will become payable to the underwriter from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.

21

Critical Accounting Policies

The preparation of condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

Warrant Liabilities

We account for the public warrants and the Private Placement Warrants in accordance with the guidance contained in Accounting Standards Codification (“ASC”) Topic 815 under which the public warrants and the Private Placement Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Under ASC Subtopic 815-40, “Derivatives and Hedging – Contracts in Entity’s Own Equity” (“ASC 815-40”), the public warrants and the Private Placement Warrants are not indexed to our common stock in the manner contemplated by ASC 815-40 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares. Accordingly, we classify the public warrants and the Private Placement Warrants as liabilities at their fair value and adjust the public warrants and the Private Placement Warrants to fair value at each reporting period. These liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our condensed statement of operations. The public warrants are valued using the closing price of the public warrants as of each relevant date. The Private Placement Warrants are valued using a Monte Carlo simulation model.

Working Capital Loan Payable

The Company accounted for the Working Capital Loan payable in accordance with ASC 470, “Debt”. The Working Capital Loan payable is recorded at amortized cost. The conversion option feature had a fair value of $0 as of on June 1, 2022, the date of initial measurement. As such, there is no debt discount recorded as there are no proceeds to allocate to the conversion option feature.

Class A Common Stock Subject to Possible Redemption

We account for our Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, Class A common stock is classified as stockholders’ equity. Our Class A common stock features certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of our condensed balance sheets.

We recognize changes in redemption value at the end of each reporting period and adjust the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Immediately upon the closing of the IPO the Company recognized the remeasurement from initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital to the extent available and accumulated deficit.

Net Income (Loss) Per Share of Common Stock

Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period in compliance with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The remeasurement associated with the redeemable Class A common stock is excluded from net income (loss) per share of common stock as the redemption value approximates fair value. The Company has not considered the effect of the warrants sold in the IPO and the 5,473,333 Private Placement Warrants in the calculation of diluted net income (loss) per share, since the exercise of the warrants is contingent upon the occurrence of future events. As a result, diluted net income (loss) per share of common stock is the same as basic net income (loss) per share of common stock for the periods presented.

The Company’s condensed statement of operations includes a presentation of net income (loss) per share of Class A common stock subject to possible redemption and non-redeemable Class B common stock and allocates the net income (loss) into the two classes of

22

shares in calculating net income (loss) per share of common stock, basic and diluted. For redeemable Class A common stock, net income (loss) per share of common stock is calculated by dividing the net income (loss) by the weighted average number of shares of Class A common stock subject to possible redemption outstanding. For non-redeemable Class B common stock, net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of nonredeemable Class B common stock outstanding for the period.

Recent Accounting Standards

In August 2020, FASB issued Accounting Standards Update No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current accounting principles generally accepted in the United States of America  (“GAAP”). ASU 2020- 06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact, if any, that ASU 2020-06 would have on our financial position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company as defined by Rule 12b-2 under the Exchange Act and are not required to provide the information otherwise required under this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended June 30, 2022, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of June 30, 2022 due to the material weakness described below.

As previously disclosed, our internal control over financial reporting did not result in the proper accounting classification and valuation of complex financial instruments, including warrants and shares subject to possible redemption that were issued in January 2021. Due to its impact on our financial statements, we determined the errors are indicative of a material weakness.

Notwithstanding the conclusion by our Chief Executive Officer and Chief Financial Officer that our disclosure controls and procedures as of June 30, 2022 were not effective, and notwithstanding the material weakness in our internal control over financial reporting described above, management believes that the unaudited condensed financial statements and related financial information included in this Quarterly Report fairly present in all material respects our financial condition, results of operations and cash flows as of the dates presented, and for the periods ended on such dates, in conformity with GAAP.

Changes in Internal Control over Financial Reporting

Except as described herein, there was no change in our internal control over financial reporting that occurred during the quarter ended June 30, 2022 covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. While we have processes to identify and appropriately apply applicable accounting requirements, we

23

plan to continue to enhance our system of evaluating and implementing the accounting standards that apply to our financial statements, including through enhanced analyses by our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

24

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be involved in various claims and legal actions in the ordinary course of business. We are not currently involved in any material legal proceedings outside the ordinary course of our business.

Item 1A. Risk Factors

As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, except for the following:

Changes in laws or regulations or how such laws or regulations are interpreted or applied, or a failure to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial Business Combination, and results of operations.

We are subject to laws and regulations enacted by national, regional and local governments. In particular, we are required to comply with certain SEC and other legal requirements, our Business Combination may be contingent on our ability to comply with certain laws and regulations and any post-Business Combination company may be subject to additional laws and regulations. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application also may change from time to time, including as a result of changes in economic, political, social and government policies, and those changes could have a material adverse effect on our business, including our ability to negotiate and complete our initial Business Combination, and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our initial Business Combination, and results of operations.

On March 30, 2022, the SEC issued proposed rules that would, among other items, impose additional disclosure requirements in business combination transactions involving special purpose acquisition companies (“SPACs”) and private operating companies; amend the financial statement requirements applicable to business combination transactions involving such companies; update and expand guidance regarding the general use of projections in SEC filings, as well as when projections are disclosed in connection with proposed business combination transactions; increase the potential liability of certain participants in proposed business combination transactions; and impact the extent to which SPACs could become subject to regulation under the Investment Company Act of 1940. These rules, if adopted, whether in the form proposed or in revised form, may materially and adversely affect our ability to negotiate and complete our initial Business Combination and may materially increase the costs and time related thereto.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Use of Proceeds

On January 28, 2021, we consummated our IPO of 31,050,000 Units, including the issuance of 4,050,000 Units as a result of the underwriter’s full exercise of its over-allotment option. Each Unit consists of one share of our Class A common stock and one-third of one warrant of the Company, with each whole warrant entitling the holder thereof to purchase one whole share of our Class A common stock at a price of $11.50 per share, subject to certain adjustments. The Units were sold at a price of $10.00 per unit, generating aggregate gross proceeds to the Company of $310,500,000. Credit Suisse Securities (USA) LLC acted as a sole underwriter of our IPO. The securities sold in our IPO were registered under the Securities Act on registration statements on Form S-1 (File Nos. 333-251987 and 333-252416). The registration statements became effective on January 25, 2021.

Following our IPO and the sale of the Private Placement Warrants, a total of $310,500,000 of the net proceeds from the sale of the Units and Private Placement Warrants was deposited in the Trust Account. Transaction costs amounted to $17,495,500, consisting of $6,210,000 of underwriting discounts and commissions, $10,867,500 of deferred underwriting discounts and commissions and $418,000 of other cash offering costs. In addition, as of June 30, 2022, $0.5 million of cash was held outside of the Trust Account and is available for working capital purposes.

For a description of the use of the net proceeds from our IPO, see Part I, Item 2 of this Quarterly Report.

25

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

26

Item 6. Exhibits

Exhibit

Number

    

Description

3.1

Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 29, 2021).

3.2

Bylaws (incorporated by reference to Exhibit 3.3 filed with the Form S-1 filed by the Registrant on January 8, 2021).

4.1

Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 filed with the Form S-1/A filed by the Registrant on January 20, 2021).

4.2

Specimen Share of Class A common stock Certificate (incorporated by reference to Exhibit 4.2 filed with the Form S-1/A filed by the Registrant on January 20, 2021).

4.3

Specimen Warrant Certificate (included in Exhibit 4.4) (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 29, 2021).

4.4

Warrant Agreement, dated January 25, 2021, between the Company and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 29, 2021).

31.1*

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101*

The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Condensed Balance Sheets; (ii) Condensed Statement of Operations; (iii) Condensed Statement of Changes in Stockholders’ Equity; (iv) Condensed Statement of Cash Flows; and (v) Notes to Condensed Financial Statements.

104*

Cover Page Interactive Data File (embedded within the Inline XBRL document)

*

Filed herewith

**

Furnished herewith

27

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Science Strategic Acquisition Corp. Alpha

Date: August 17, 2022

By:

/s/ Michael Jones

Mr. Michael Jones

Chief Executive Officer

(principal executive officer)

Date: August 17, 2022

By:

/s/ Thomas Dare

Mr. Thomas Dare

Chief Financial Officer

(principal financial and accounting officer)

28

EX-31.1 2 ssaau-20220630xex31d1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Jones, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Science Strategic Acquisition Corp. Alpha;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 17, 2022

By:

/s/ Michael Jones

Michael Jones

Chief Executive Officer

(Principal Executive Officer)


EX-31.2 3 ssaau-20220630xex31d2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Thomas Dare, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Science Strategic Acquisition Corp. Alpha;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 17, 2022

 

By:

 

/s/ Thomas Dare

 

 

 

 

Thomas Dare

 

 

 

 

Chief Financial Officer

(Principal Financial and Accounting Officer)


EX-32.1 4 ssaau-20220630xex32d1.htm EXHIBIT 32.1

 Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Science Strategic Acquisition Corp. Alpha (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, in the capacity and on the date indicated below, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 17, 2022

    

By:

  

/s/ Michael Jones

 

Michael Jones

Chief Executive Officer
(Principal Executive Officer)


EX-32.2 5 ssaau-20220630xex32d2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Science Strategic Acquisition Corp. Alpha (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, in the capacity and on the date indicated below, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

7

Date: August 17, 2022

By: /s/ Thomas Dare

Thomas Dare

Chief Financial Officer

(Principal Financial and Accounting

Officer)


EX-101.SCH 6 ssaau-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Statements of Changes in Stockholders' Deficit (unaudited) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Condensed Statements of Changes in Stockholders' Deficit (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Company's Condensed Statements of Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net income per common share (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - INITIAL PUBLIC OFFERING (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - PRIVATE PLACEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - STOCKHOLDERS' DEFICIT - Common Stock Shares (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value Measurements Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - INITIAL PUBLIC OFFERING link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - PRIVATE PLACEMENT link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - INCOME TAX link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - STOCKHOLDERS' DEFICIT - Preferred Stock Shares (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ssaau-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 ssaau-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 ssaau-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 ssaau-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2022
Aug. 17, 2022
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2022  
Entity File Number 001-39930  
Entity Registrant Name Science Strategic Acquisition Corp. Alpha  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-3594633  
Entity Address, Address Line One 1447 2nd Street  
Entity Address, City or Town Santa Monica  
Entity Address State Or Province CA  
Entity Address, Postal Zip Code 90401  
City Area Code 310  
Local Phone Number 393-3024  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company true  
Entity Central Index Key 0001830547  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Unit Each Consisting Of One Class Common Stock And One Third of one Redeemable Warrant    
Document Information [Line Items]    
Title of 12(b) Security Units, each consisting of one share of Class A common stock, $0.0001 par value, and one-third of one redeemable warrant  
Trading Symbol SSAAU  
Security Exchange Name NASDAQ  
Class A Common Stock    
Document Information [Line Items]    
Title of 12(b) Security Class A common stock  
Trading Symbol SSAA  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   31,050,000
Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50    
Document Information [Line Items]    
Title of 12(b) Security Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50  
Trading Symbol SSAAW  
Security Exchange Name NASDAQ  
Class B Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   7,762,500
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Balance Sheets - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Current assets    
Cash $ 511,761 $ 346,319
Prepaid expenses - current 239,075 337,104
Total Current Assets 750,836 683,423
Noncurrent assets    
Marketable securities held in Trust Account 310,780,579 310,544,829
Prepaid expenses - noncurrent 0 27,689
Total Noncurrent Assets 310,780,579 310,572,518
TOTAL ASSETS 311,531,415 311,255,941
Current liabilities    
Accrued offering costs 0 70,000
Related party payables 19,244 250,000
Working capital loan payable 750,000 0
Accrued expenses 1,565,164 1,315,635
Total Current Liabilities 2,334,408 1,635,635
Noncurrent liabilities    
Warrant liability 1,424,100 8,544,600
Deferred underwriting fee payable 10,867,500 10,867,500
Total Noncurrent Liabilities 12,291,600 19,412,100
Total Liabilities 14,626,008 21,047,735
Commitments and Contingencies (Note 7)
Stockholders' Deficit    
Preferred stock, $0.0001 par value; 1,000,000 authorized; none issued and outstanding 0 0
Additional paid-in capital 0 0
Accumulated deficit (13,595,369) (20,292,570)
Total Stockholders' Deficit (13,594,593) (20,291,794)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT 311,531,415 311,255,941
Class A Common Stock Subject to Redemption    
Noncurrent liabilities    
Class A Common stock subject to possible redemption, 31,050,000 shares at redemption value as of June 30, 2022 and December 31, 2021 310,500,000 310,500,000
Class A Common Stock Not Subject to Redemption    
Stockholders' Deficit    
Common stock 0 0
Class B Common Stock    
Stockholders' Deficit    
Common stock $ 776 $ 776
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Preferred stock, par value, (per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Class A Common Stock    
Common shares, par value, (per share) $ 0.0001 $ 0.0001
Common shares, shares authorized 400,000,000 400,000,000
Common shares, shares issued 0 0
Common shares, shares outstanding 0 0
Class A Common Stock Subject to Redemption    
Temporary equity, shares outstanding 31,050,000 31,050,000
Class A Common Stock Not Subject to Redemption    
Common shares, shares issued 0 0
Common shares, shares outstanding 0 0
Class B Common Stock    
Common shares, par value, (per share) $ 0.0001 $ 0.0001
Common shares, shares authorized 40,000,000 40,000,000
Common shares, shares issued 7,762,500 7,762,500
Common shares, shares outstanding 7,762,500 7,762,500
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Operations (unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating expenses $ 341,179 $ 211,844 $ 659,049 $ 729,474
Loss from operations (341,179) (211,844) (659,049) (729,474)
Other income (expense):        
Unrealized gain on marketable securities held in Trust Account 231,412 6,774 235,750 34,744
Change in fair value of warrant liability 2,057,033 (3,986,035) 7,120,500 (1,929,002)
Total other income (expense) 2,288,445 (3,979,261) 7,356,250 (1,894,258)
Net income (loss) 1,947,266 (4,191,105) 6,697,201 (2,623,732)
Class A Common Stock Subject to Redemption        
Other income (expense):        
Net income (loss) $ 1,557,813 $ (3,352,884) $ 5,357,761 $ (2,032,003)
Weighted average number of shares outstanding, Basic 31,050,000 31,050,000 31,050,000 26,102,473
Weighted average number of shares outstanding, Diluted 31,050,000 31,050,000 31,050,000 26,102,473
Net income (loss) per share, Basic $ 0.05 $ (0.11) $ 0.17 $ (0.08)
Net income (loss) per share, Diluted $ 0.05 $ (0.11) $ 0.17 $ (0.08)
Non redeemable Class B common stock        
Other income (expense):        
Net income (loss) $ 389,453 $ (838,221) $ 1,339,440 $ (591,729)
Weighted average number of shares outstanding, Basic 7,762,500 7,762,500 7,762,500 7,601,168
Weighted average number of shares outstanding, Diluted 7,762,500 7,762,500 7,762,500 7,601,168
Net income (loss) per share, Basic $ 0.05 $ (0.11) $ 0.17 $ (0.08)
Net income (loss) per share, Diluted $ 0.05 $ (0.11) $ 0.17 $ (0.08)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Changes in Stockholders' Deficit (unaudited) - USD ($)
Class A Common Stock Subject to Redemption
Common Stock
Class A Common Stock Subject to Redemption
Class B Common Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at the beginning at Dec. 31, 2020     $ 776 $ 24,224 $ (5,000) $ 20,000
Balance at the beginning (in shares) at Dec. 31, 2020     7,762,500      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Proceeds received in excess of fair value of public warrants       4,159,734   4,159,734
Remeasurement of Class A common stock subject to possible redemption       (4,183,958) (20,446,345) (24,630,303)
Net income         1,567,374 1,567,374
Balance at the end at Mar. 31, 2021     $ 776   (18,883,971) (18,883,195)
Balance at the end (in shares) at Mar. 31, 2021     7,762,500      
Increase (Decrease) in Temporary Equity [Roll Forward]            
Issuance of 31,050,000 Units $ 285,869,697          
Issuance of 31,050,000 Units (in shares) 31,050,000          
Remeasurement of Class A common stock subject to possible redemption $ 24,630,303          
Balance at the end at Mar. 31, 2021 $ 310,500,000          
Balance at the end (in shares) at Mar. 31, 2021 31,050,000          
Balance at the beginning at Dec. 31, 2020     $ 776 24,224 (5,000) 20,000
Balance at the beginning (in shares) at Dec. 31, 2020     7,762,500      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income   $ (2,032,003)       (2,623,732)
Balance at the end at Jun. 30, 2021     $ 776   (23,075,076) (23,074,300)
Balance at the end (in shares) at Jun. 30, 2021     7,762,500      
Balance at the end at Jun. 30, 2021 $ 310,500,000          
Balance at the end (in shares) at Jun. 30, 2021 31,050,000          
Balance at the beginning at Mar. 31, 2021     $ 776   (18,883,971) (18,883,195)
Balance at the beginning (in shares) at Mar. 31, 2021     7,762,500      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income   (3,352,884)     (4,191,105) (4,191,105)
Balance at the end at Jun. 30, 2021     $ 776   (23,075,076) (23,074,300)
Balance at the end (in shares) at Jun. 30, 2021     7,762,500      
Balance at the beginning at Mar. 31, 2021 $ 310,500,000          
Balance at the beginning (in shares) at Mar. 31, 2021 31,050,000          
Balance at the end at Jun. 30, 2021 $ 310,500,000          
Balance at the end (in shares) at Jun. 30, 2021 31,050,000          
Balance at the beginning at Dec. 31, 2021     $ 776 0 (20,292,570) (20,291,794)
Balance at the beginning (in shares) at Dec. 31, 2021     7,762,500      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income         4,749,935 4,749,935
Balance at the end at Mar. 31, 2022     $ 776   (15,542,635) (15,541,859)
Balance at the end (in shares) at Mar. 31, 2022     7,762,500      
Balance at the beginning at Dec. 31, 2021 $ 310,500,000          
Balance at the beginning (in shares) at Dec. 31, 2021 31,050,000          
Balance at the end at Mar. 31, 2022 $ 310,500,000          
Balance at the end (in shares) at Mar. 31, 2022 31,050,000          
Balance at the beginning at Dec. 31, 2021     $ 776 $ 0 (20,292,570) (20,291,794)
Balance at the beginning (in shares) at Dec. 31, 2021     7,762,500      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income   5,357,761       6,697,201
Balance at the end at Jun. 30, 2022     $ 776   (13,595,369) (13,594,593)
Balance at the end (in shares) at Jun. 30, 2022     7,762,500      
Balance at the beginning at Dec. 31, 2021 $ 310,500,000          
Balance at the beginning (in shares) at Dec. 31, 2021 31,050,000          
Balance at the end at Jun. 30, 2022 $ 310,500,000          
Balance at the end (in shares) at Jun. 30, 2022 31,050,000          
Balance at the beginning at Mar. 31, 2022     $ 776   (15,542,635) (15,541,859)
Balance at the beginning (in shares) at Mar. 31, 2022     7,762,500      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income   $ 1,557,813     1,947,266 1,947,266
Balance at the end at Jun. 30, 2022     $ 776   $ (13,595,369) $ (13,594,593)
Balance at the end (in shares) at Jun. 30, 2022     7,762,500      
Balance at the beginning at Mar. 31, 2022 $ 310,500,000          
Balance at the beginning (in shares) at Mar. 31, 2022 31,050,000          
Balance at the end at Jun. 30, 2022 $ 310,500,000          
Balance at the end (in shares) at Jun. 30, 2022 31,050,000          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Changes in Stockholders' Deficit (unaudited) (Parenthetical)
3 Months Ended
Mar. 31, 2021
shares
Class A Common Stock Subject to Redemption | Common Stock  
Issuance of units 31,050,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Cash Flows (unaudited) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash Flows used in Operating Activities:    
Net income (loss) $ 6,697,201 $ (2,623,732)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Unrealized gain on marketable securities held in Trust Account (235,750) (34,744)
Change in fair value of warrant liability (7,120,500) 1,929,002
Warrant issuance costs   420,743
Changes in operating assets and liabilities:    
Prepaid expenses, net of amortization 125,718 (566,520)
Related party payable (230,756)  
Accrued offering costs (70,000)  
Accrued expenses 249,529 2,018
Net cash used in operating activities (584,558) (873,233)
Cash Flows from Investing Activities:    
Investment of cash in Trust Account   (310,500,000)
Net cash used in investing activities   (310,500,000)
Cash Flows from Financing Activities:    
Proceeds from sale of Units, net of underwriting discounts paid   304,290,000
Proceeds from the sale of Private Placements Warrants   8,210,000
Proceeds from promissory note - related party   300,000
Repayment of promissory note - related party   (300,000)
Proceeds from working capital loan 750,000  
Payment of offering costs   (278,045)
Net cash provided by financing activities 750,000 312,221,955
Net Change in Cash 165,442 848,722
Cash - Beginning of period 346,319 20,000
Cash - End of period $ 511,761 868,722
Non-Cash investing and financing activities:    
Initial classification of Class A common stock subject to possible redemption   285,869,697
Remeasurement of Class A common stock subject to possible redemption   24,630,303
Initial fair value of warrant liability   11,605,766
Deferred offering costs included in accrued offering costs   $ 135,000
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION AND PLANS OF BUSINESS OPERATIONS
6 Months Ended
Jun. 30, 2022
ORGANIZATION AND PLANS OF BUSINESS OPERATIONS  
ORGANIZATION AND PLANS OF BUSINESS OPERATIONS

NOTE 1. ORGANIZATION AND PLANS OF BUSINESS OPERATIONS

Organization and General

Science Strategic Acquisition Corp. Alpha (the “Company”) was incorporated in Delaware on October 22, 2020. The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”). The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

Sponsor and Initial Financing

As of June 30, 2022, the Company had not commenced any operations. All activity through June 30, 2022 relates to the Company’s formation, the initial public offering (the “Initial Public Offering”), which is described below, and identifying a target for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering, and non-operating income or expenses from the change in fair value of warrant liability.

The registration statements for the Initial Public Offering were declared effective on January 25, 2021. On January 28, 2021, the Company consummated the Initial Public Offering of 31,050,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), which includes the exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at $10.00 per Unit, generating gross proceeds of $310,500,000, which is described in Note 4.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,473,333 warrants (each, a “Private Placement Warrant” and, collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to SSAC Alpha Sponsor, LLC (the “Sponsor”), generating gross proceeds of $8,210,000, which is described in Note 5.

Transaction costs amounted to $17,495,500, consisting of $6,210,000 of underwriting fees, $10,867,500 of deferred underwriting fees and $418,000 of other offering costs. In addition, cash of approximately $2,300,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.

The Trust Account

Following the closing of the Initial Public Offering on January 28, 2021, an amount of $310,500,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”). The funds in the Trust Account will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended. The Company will not be permitted to withdraw any of the principal or interest held in the Trust Account except for the withdrawal of interest to pay taxes, if any. The funds held in the Trust Account will not otherwise be released from the trust account until the earliest of: (1) the Company’s completion of a Business Combination; (2) the redemption of any Public Shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete a Business Combination on or before January 28, 2023 or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity; and (3) the redemption of the Company’s Public Shares if the Company has not completed a Business Combination on or before January 28, 2023, subject to applicable law. Based on current interest rates, the Company expects that interest earned on the Trust Account will be sufficient to pay taxes.

Business Combination

The Company’s management has broad discretion with respect to the specific application of the net proceeds from the Initial Public Offering, although substantially all of the net proceeds from the Initial Public Offering are intended to be generally applied toward consummating a Business Combination with (or acquisition of) a Target Business. As used herein, “Target Business” means one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the Trust Account (excluding taxes payable on the interest earned on the Trust Account) at the time of the signing of a definitive agreement in connection with a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully effect a Business Combination.

The Company will provide its public stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination, either (i) in connection with a stockholder meeting called to approve such Business Combination or (ii) by means of a tender offer. The public stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account, calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to the public stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 7). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.

The decision as to whether the Company will seek stockholder approval of a Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, in its sole discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval unless a vote is required by law or stock exchange listing requirements. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the shares of common stock voted are voted in favor of a Business Combination. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 upon consummation of a Business Combination. In such case, the Company would not proceed with the redemption of its Public Shares and the related Business Combination, and instead may search for an alternate Business Combination.

The Company will have until January 28, 2023 to complete its initial Business Combination. If the Company does not complete a Business Combination by such date (or such longer period as provided in an amendment to the Company’s amended and restated certificate of incorporation approved by its stockholders (an “Extension Period”)), it shall (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. The initial stockholders have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares (as defined in Note 6) if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. However, if the initial stockholders acquire Public Shares, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period.

The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to have all third parties, including, but not limited to, all vendors, service providers (other than its independent registered public accounting firm), prospective target businesses and other entities with which the Company does business execute agreements with the Company waiving any right, title, interest or claims of any kind in or to any monies held in the Trust Account.

Liquidity, Capital Resources and Going Concern

As of June 30, 2022, the Company had $511,761 in cash held outside of the Trust Account and a working capital deficit of $1,483,572.

The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor to cover certain offering costs on the Company’s behalf in exchange for the issuance of Founder Shares (as discussed in Note 6), and a loan from the Sponsor of $300,000 under the Promissory Note (as discussed in Note 6). The Company repaid the Promissory Note in full on February 2, 2021. Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the private placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Sponsor may provide up to $750,000 to the Company as a working capital loan (the “Working Capital Loan”) (as discussed in Note 6). As of June 30, 2022 and December 31, 2021, there was $750,000 and $0 outstanding under the Working Capital Loan, respectively. In order to fund working capital deficiencies or finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s directors and officers may, but are not obligated to, loan the Company additional funds (“Additional Working Capital Loans”) as may be required.

The Company has incurred and expects to incur significant costs in pursuit of its financing and acquisition plans. Management believes that the Company has access to funds from the Sponsor that are sufficient to fund the working capital needs of the Company until the consummation of an initial Business Combination or for a minimum of one year from the date of issuance of these financial statements. However, in connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Company’s cash flow deficit and the liquidation date of January 28, 2023 being within twelve months from the issuance of these financial statements raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. There is no assurance that the Company’s plans to consummate a Business Combination or raise additional funds will be successful. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
6 Months Ended
Jun. 30, 2022
REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS  
REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

NOTE 2. REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

In connection with the preparation of the Company's financial statements as of June 30, 2022, management identified an error made in its historical financial statements where, warrant issuance costs were incorrectly included within the financing activities section of the Statement of Cash Flows as of June 30, 2021. The Company revised the Condensed Statements of Cash Flows by reclassifying warrant issuance costs from financing activities to operating activities for the six months ended June 30, 2021.

The impact of the revision on the Company’s Condensed Statements of Cash Flows is reflected in the following table:

    

As Previously Reported

    

As Revised

For the Six Months Ended

For the Six Months Ended

June 30, 2021

June 30, 2021

Cash Flows Used in Operating Activities:

 

  

 

  

Warrant issuance costs

 

 

420,743

Net cash used in operating activities

 

(1,293,976)

 

(873,233)

Cash Flows From Financing Activities:

 

  

 

  

Proceeds from sale of Units, net of underwriting discounts paid

 

304,710,744

 

304,290,000

Net cash provided by financing activities

 

312,642,698

 

312,221,955

There is no impact to the reported amounts for total assets, total liabilities, or net income.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on April 12, 2022, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2021 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2022 and December 31, 2021.

Offering Costs

Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.

Marketable Securities Held in Trust Account

At June 30, 2022, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities. Through June 30, 2022, the Company has not withdrawn any monies from the Trust Account.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The provision for income taxes was deemed to be de minimis for the three and six months ended June 30, 2022.

Net Income (Loss) per Share

Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period in compliance with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings per Share.” The remeasurement associated with the redeemable Class A common stock is excluded from net income (loss) per share as the redemption value approximates fair value. The Company has not considered the effect of the warrants sold in the Initial Public Offering

and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted net income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods presented.

The Company’s condensed statement of operations includes a presentation of net income (loss) per share of Class A common stock subject to possible redemption and non-redeemable Class B common stock and allocates the net income (loss) into the two classes of stock in calculating net income (loss). Net income (loss) per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class A common stock subject to possible redemption outstanding. Net income (loss) per share, basic and diluted, for Class B non-redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class B non-redeemable common stock outstanding for the period. As of June 30, 2022 and June 30, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercisable or converted to shares of common stock and then share in the earnings of the Company.

The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts):

For the Three Months Ended

For the Six Months Ended

June 30,

June 30, 

2022

2021

2022

2021

    

(unaudited)

(unaudited)

    

(unaudited)

    

(unaudited)

Class A common stock subject to possible redemption

 

  

 

  

Numerator: Net income (loss) attributable to Class A Common Stock subject to possible redemption

 

  

 

  

Net income (loss)

$

1,557,813

$

(3,352,884)

$

5,357,761

$

(2,032,003)

Net income (loss) attributable to Class A common stock subject to possible redemption

$

1,557,813

$

(3,352,884)

$

5,357,761

$

(2,032,003)

Denominator: Weighted average Class A common stock subject to possible redemption

Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption

31,050,000

31,050,000

31,050,000

26,102,473

Basic and diluted net income (loss) per share, Class A Common Stock subject to possible redemption

$

0.05

$

(0.11)

$

0.17

$

(0.08)

Non-Redeemable Class B Common Stock

Numerator: Net income (loss) attributable to Class B common stock

Net income (loss)

$

389,453

$

(838,221)

1,339,440

$

(591,729)

Non-redeemable net income (loss)

$

389,453

$

(838,221)

$

1,339,440

$

(591,729)

Denominator: Weighted average shares of non-redeemable Class B common stock

Basic and diluted weighted average shares outstanding, non-redeemable Class B common stock

7,762,500

7,762,500

7,762,500

7,601,168

Basic and diluted net income (loss) per share, non-redeemable Class B common stock

$

0.05

$

(0.11)

0.17

$

(0.08)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Warrants Exercisable for Class A Common Stock

The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, “Derivatives and Hedging” (“ASC 815”). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

Working Capital Loan Payable

The Company accounted for the Working Capital Loan payable in accordance with ASC 470, “Debt”. The Working Capital Loan payable is recorded at amortized cost. The conversion option feature had a fair value of $0 as of on June 1, 2022, the date of initial measurement. As such, there is no debt discount recorded as there are no proceeds to allocate to the conversion option feature.

Class A Common Stock Subject to Possible Redemption

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheets.

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Such changes are reflected in additional paid-in capital to the extent available, or in the absence of additional capital, in accumulated deficit.

At June 30, 2022 and December 31, 2021, the Class A common stock subject to possible redemption reflected in the condensed balance sheets is reconciled in the following table:

Gross proceeds from initial public offering

    

$

310,500,000

Less:

 

  

Proceeds allocated to public warrants

 

(7,555,500)

Offering costs allocated to Class A common stock subject to possible redemption

 

(17,074,803)

Add:

 

  

Remeasurement on Class A common stock subject to possible redemption amount

 

24,630,303

Class A common stock subject to possible redemption

$

310,500,000

Recent Accounting Pronouncements

In August 2020, FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
INITIAL PUBLIC OFFERING
6 Months Ended
Jun. 30, 2022
INITIAL PUBLIC OFFERING  
INITIAL PUBLIC OFFERING

NOTE 4. INITIAL PUBLIC OFFERING

On January 28, 2021, pursuant to the Initial Public Offering, the Company sold 31,050,000 Units, which includes the full exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and one-third of one redeemable warrant (each whole warrant, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment (see Note 9).

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
PRIVATE PLACEMENT
6 Months Ended
Jun. 30, 2022
PRIVATE PLACEMENT  
PRIVATE PLACEMENT

NOTE 5. PRIVATE PLACEMENT

Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 5,473,333 Private Placement Warrants, at a price of $1.50 per Private Placement Warrant, for an aggregate purchase price of $8,210,000 in a private placement. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share. $6,210,000 of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination by January 28, 2023 or during any Extension Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2022
RELATED PARTY TRANSACTIONS  
RELATED PARTY TRANSACTIONS

NOTE 6. RELATED PARTY TRANSACTIONS

Founder Shares

On October 29, 2020, the Sponsor purchased 6,468,750 shares of Class B common stock for an aggregate purchase price of $25,000. On January 25, 2021, the Company effected a stock dividend of 1,293,750 shares of Class B common stock to holders of Class B common stock on a pro rata basis based on their holdings, resulting in the Company’s initial stockholders holding an aggregate of 7,762,500 shares of Class B common stock (see Note 8). All share and per-share amounts have been retroactively restated to reflect the stock dividend.

The initial stockholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Class B common stock or Class A common stock received upon conversion thereof (together, “Founder Shares”) until the earlier of: (A) one year after the completion of a Business Combination; and (B) subsequent to a Business Combination (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of common stock for cash, securities or other property.

Promissory Note — Related Party

On October 29, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Promissory Note”). The Promissory Note was non-interest bearing and payable on the earlier of December 31, 2021 or the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $300,000 remained outstanding at the closing of the Initial Public Offering on January 28, 2021. On February 2, 2021, the Company repaid the Promissory Note in full.

Administrative Services Agreement

The Company agreed, commencing on the date that securities of the Company were first listed on the Nasdaq Capital Market through the earlier of the Company’s consummation of a Business Combination or its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, administrative and support services. The Company and the affiliate of the Sponsor canceled the Administrative Services Agreement effective March 31, 2022 as the affiliate of the Sponsor agreed to waive the monthly payments. No amounts have been accrued or paid for the period from the commencement date through June 30, 2022.

Related Party Payables

The Company owed $19,244 and $250,000 as of June 30, 2022 and December 31, 2021, respectively, to a related party for certain costs paid by an affiliate of the Sponsor.

Working Capital Loan

On May 27, 2022, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Sponsor may provide up to $750,000 to the Company as a working capital loan. The Working Capital Loan does not bear interest and is repayable in full on the earlier of (i) the consummation of the Company’s initial Business Combination or (ii) end of the Business Combination period. Upon the consummation of a Business Combination, the Sponsor shall have the option, but not the obligation, to convert the principal balance of the Working Capital Loan, in whole or in part, into warrants at a price of $1.50 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loan but no proceeds held in the Trust Account would be used to repay the Working Capital Loan. The Working Capital Loan is subject to customary events of default, the occurrence of which automatically trigger the unpaid principal balance of the Working Capital Loan and all other sums payable with regard to the Working Capital Loan becoming immediately due and payable. As of June 30, 2022 and December 31, 2021, there was $750,000 and $0 outstanding under the Working Capital Loan, respectively.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2022
COMMITMENTS AND CONTINGENCIES  
COMMITMENTS AND CONTINGENCIES

NOTE 7. COMMITMENTS AND CONTINGENCIES

Registration Rights

The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued on conversion of the Working Capital Loan or Additional Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loan or Additional Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement signed in conjunction with the Initial Public Offering requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Company’s Class A common stock). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,867,500 in the aggregate. The deferred fee will be waived by the underwriters in the event that the Company does not complete a Business Combination by January 28, 2023, subject to the terms of the underwriting agreement.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' DEFICIT
6 Months Ended
Jun. 30, 2022
STOCKHOLDERS' DEFICIT  
STOCKHOLDERS' DEFICIT

NOTE 8. STOCKHOLDERS’ DEFICIT

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The board of directors is able to, without stockholder approval, issue shares of preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the common stock and could have anti-takeover effects. At June 30, 2022 and December 31, 2021, there were no shares of preferred stock issued or outstanding.

Class A Common Stock — The Company is authorized to issue 400,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were no shares of Class A common stock issued and outstanding, excluding 31,050,000 shares of Class A common stock subject to possible redemption, which are presented as temporary equity.

Class B Common Stock — The Company is authorized to issue 40,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were 7,762,500 shares of Class B common stock issued and outstanding.

Holders of Class B common stock have the right to elect all of the Company’s directors prior to a Business Combination. Holders of Class A common stock and Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders except as required by law.

The Class B common stock will automatically convert into Class A common stock at the time of the completion of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which Founder Shares will convert into Class A common stock will be adjusted (subject to waiver by holders of a majority of the Class B common stock) so that the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of the common stock issued and outstanding upon completion of the Initial Public Offering plus the number of shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination, excluding any shares of Class A common stock or equity-linked securities issued, or to be issued, to any seller in a Business Combination.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
WARRANTS
6 Months Ended
Jun. 30, 2022
WARRANTS  
WARRANTS

NOTE 9. WARRANTS

Warrants— Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months after the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement governing the Warrants (the “Warrant Agreement”). The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However except as described below, the warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination by January 28, 2023 or during an Extension Period and the Company liquidates the funds held in the Trust Account, holders of the warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution form the Company’s assets held outside the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.

In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the completion of the Company’s initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of shares of the Company’s Class A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummate a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00” and “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.

The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration or a valid exemption from registration is available. No Public Warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their Public Warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.

The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement registering the issuance, under the Securities Act, of the Class A common stock issuable upon exercise of the Public Warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the Warrant Agreement. Notwithstanding the above, if the Class A common stock is, at the time of any exercise of a Public Warrant, not listed on a national securities exchange such that they do not satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their Public Warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:

in whole and not in part;
at a price of $0.01 per Public Warrant;
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
if, and only if, the last reported sale price of shares of the Class A common stock for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant).

Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:

in whole and not in part;
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the “fair market value” of the Class A common stock;
if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted); and
if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants.

If and when the Public Warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

The Private Placement Warrants are identical to the Public Warrants underlying the Units that were sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and are exercisable by such holders on the same basis as the Public Warrants.

The Warrants are not considered to be indexed to the Company’s stock price. In accordance with ASC 815, the warrants were classified as a liability in the total amount of $11.6 million at January 28, 2021. In addition, the warrants must be valued every reporting period and adjusted to market value with the increase or decrease being adjusted through earnings. As of June 30, 2022 and December 31, 2021, the fair value of the warrant liability was $1,424,100 and $8,544,600, respectively.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2022
FAIR VALUE MEASUREMENTS  
FAIR VALUE MEASUREMENTS

NOTE 10. FAIR VALUE MEASUREMENTS

The following table presents fair value information at June 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. The Company’s warrant liability is based on a valuation model utilizing management’s judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair value of the Private Placement Warrants liability is classified within Level 3 of the fair value hierarchy. There was no transfer of fair value measurements between levels of the fair value hierarchy for the three and six months ended June 30, 2022.

The following tables set forth by level within the fair value hierarchy the Company’s assets and liabilities that were accounted for at fair value on a recurring basis:

    

June 30, 2022 (unaudited)

    

(Level 1)

    

(Level 2)

    

(Level 3)

Assets

 

  

 

  

 

  

Cash and marketable securities held in Trust Account

$

310,780,579

$

$

Liabilities

 

 

  

 

  

Public Warrants

$

931,500

$

$

Private Placement Warrants

$

$

$

492,600

    

December 31, 2021

    

(Level 1)

    

(Level 2)

    

(Level 3)

Assets

  

  

  

Cash and marketable securities held in Trust Account

$

310,544,829

$

$

Liabilities

 

 

  

 

  

Public Warrants

$

5,589,000

$

$

Private Placement Warrants

$

$

$

2,955,600

Measurement

At June 30, 2022, the Company’s warrant liability was valued at $1,424,100. Under the guidance in Subtopic 815-40, the Public Warrants and the Private Placement Warrants do not meet the criteria for equity treatment. As such, the Public Warrants and the Private Placement Warrants must be recorded as a liability on the balance sheet at fair value. This valuation is subject to re-measurement at each balance sheet date. With each re-measurement, the valuations will be adjusted to fair value, with the change in fair value recognized in the Company’s condensed statement of operations.

The Warrants were initially valued using a Monte Carlo simulation model, with the observable assumptions as provided in the table below. Significant increases in the expected stock prices and expected liquidity would result in a significantly higher fair value measurement. Significant increases in either the probability or severity of default of the host instrument would result in a significantly lower fair value measurement. The measurement of the Public Warrants after the detachment of the Public Warrants from the Units is classified as Level 1 due to the use of an observable market quote in an active market. For periods subsequent to the detachment of the Public Warrants from the Units, the closing price of the Public Warrants was used as the fair value for the Public Warrants as of each relevant date. The Private Placement Warrants are valued using a Monte Carlo simulation model at each reporting period.

The key inputs into the Monte Carlo simulation model formula utilized to value the Private Placement Warrants were as follows at June 30, 2022 and December 31, 2021:

June 30, 

December 31, 

Input

    

2022

    

2021

Common stock price

$

9.81

$

9.75

Exercise price

$

11.50

$

11.50

Risk-free rate of interest

 

2.97

%

1.34

%

Volatility

 

6.31

%

9.10

%

Term

 

5.51

6.00

Warrant to buy one share (unadjusted for the probability of dissolution)

$

0.60

$

0.54

Warrant to buy one share (adjusted for the probability of dissolution)

$

0.09

$

0.54

Dividend yield

0.00

%

0.00

%

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
INCOME TAX
6 Months Ended
Jun. 30, 2022
INCOME TAX  
INCOME TAX

NOTE 11. INCOME TAX

During the three and six months ended June 30, 2022, the Company did not record any income tax benefits for the net operating losses incurred due to the uncertainty of realizing a benefit from those items. Taxes generated on the interest income on amounts held in the Trust Account are offset by the net operating losses and valuation allowance.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company considered the history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies, and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As such, the Company recorded a full valuation allowance against net deferred tax assets as of June 30, 2022 and December 31, 2021.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2022
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

NOTE 12. SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on April 12, 2022, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2021 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.

Emerging Growth Company

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2022 and December 31, 2021.

Offering Costs

Offering Costs

Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.

Marketable Securities Held in Trust Account

Marketable Securities Held in Trust Account

At June 30, 2022, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities. Through June 30, 2022, the Company has not withdrawn any monies from the Trust Account.

Income Taxes

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The provision for income taxes was deemed to be de minimis for the three and six months ended June 30, 2022.

Net Income (Loss) per Share

Net Income (Loss) per Share

Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period in compliance with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings per Share.” The remeasurement associated with the redeemable Class A common stock is excluded from net income (loss) per share as the redemption value approximates fair value. The Company has not considered the effect of the warrants sold in the Initial Public Offering

and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted net income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods presented.

The Company’s condensed statement of operations includes a presentation of net income (loss) per share of Class A common stock subject to possible redemption and non-redeemable Class B common stock and allocates the net income (loss) into the two classes of stock in calculating net income (loss). Net income (loss) per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class A common stock subject to possible redemption outstanding. Net income (loss) per share, basic and diluted, for Class B non-redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class B non-redeemable common stock outstanding for the period. As of June 30, 2022 and June 30, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercisable or converted to shares of common stock and then share in the earnings of the Company.

The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts):

For the Three Months Ended

For the Six Months Ended

June 30,

June 30, 

2022

2021

2022

2021

    

(unaudited)

(unaudited)

    

(unaudited)

    

(unaudited)

Class A common stock subject to possible redemption

 

  

 

  

Numerator: Net income (loss) attributable to Class A Common Stock subject to possible redemption

 

  

 

  

Net income (loss)

$

1,557,813

$

(3,352,884)

$

5,357,761

$

(2,032,003)

Net income (loss) attributable to Class A common stock subject to possible redemption

$

1,557,813

$

(3,352,884)

$

5,357,761

$

(2,032,003)

Denominator: Weighted average Class A common stock subject to possible redemption

Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption

31,050,000

31,050,000

31,050,000

26,102,473

Basic and diluted net income (loss) per share, Class A Common Stock subject to possible redemption

$

0.05

$

(0.11)

$

0.17

$

(0.08)

Non-Redeemable Class B Common Stock

Numerator: Net income (loss) attributable to Class B common stock

Net income (loss)

$

389,453

$

(838,221)

1,339,440

$

(591,729)

Non-redeemable net income (loss)

$

389,453

$

(838,221)

$

1,339,440

$

(591,729)

Denominator: Weighted average shares of non-redeemable Class B common stock

Basic and diluted weighted average shares outstanding, non-redeemable Class B common stock

7,762,500

7,762,500

7,762,500

7,601,168

Basic and diluted net income (loss) per share, non-redeemable Class B common stock

$

0.05

$

(0.11)

0.17

$

(0.08)

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.

Fair Value Measurements

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Warrants Exercisable for Class A Common Stock

Warrants Exercisable for Class A Common Stock

The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, “Derivatives and Hedging” (“ASC 815”). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

Working Capital Loan Payable

Working Capital Loan Payable

The Company accounted for the Working Capital Loan payable in accordance with ASC 470, “Debt”. The Working Capital Loan payable is recorded at amortized cost. The conversion option feature had a fair value of $0 as of on June 1, 2022, the date of initial measurement. As such, there is no debt discount recorded as there are no proceeds to allocate to the conversion option feature.

Class A Common Stock Subject to Possible Redemption

Class A Common Stock Subject to Possible Redemption

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheets.

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Such changes are reflected in additional paid-in capital to the extent available, or in the absence of additional capital, in accumulated deficit.

At June 30, 2022 and December 31, 2021, the Class A common stock subject to possible redemption reflected in the condensed balance sheets is reconciled in the following table:

Gross proceeds from initial public offering

    

$

310,500,000

Less:

 

  

Proceeds allocated to public warrants

 

(7,555,500)

Offering costs allocated to Class A common stock subject to possible redemption

 

(17,074,803)

Add:

 

  

Remeasurement on Class A common stock subject to possible redemption amount

 

24,630,303

Class A common stock subject to possible redemption

$

310,500,000

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In August 2020, FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)
6 Months Ended
Jun. 30, 2022
REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS  
Schedule of impact of the revision on financial statements

The impact of the revision on the Company’s Condensed Statements of Cash Flows is reflected in the following table:

    

As Previously Reported

    

As Revised

For the Six Months Ended

For the Six Months Ended

June 30, 2021

June 30, 2021

Cash Flows Used in Operating Activities:

 

  

 

  

Warrant issuance costs

 

 

420,743

Net cash used in operating activities

 

(1,293,976)

 

(873,233)

Cash Flows From Financing Activities:

 

  

 

  

Proceeds from sale of Units, net of underwriting discounts paid

 

304,710,744

 

304,290,000

Net cash provided by financing activities

 

312,642,698

 

312,221,955

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of basic and diluted net income per common share

The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts):

For the Three Months Ended

For the Six Months Ended

June 30,

June 30, 

2022

2021

2022

2021

    

(unaudited)

(unaudited)

    

(unaudited)

    

(unaudited)

Class A common stock subject to possible redemption

 

  

 

  

Numerator: Net income (loss) attributable to Class A Common Stock subject to possible redemption

 

  

 

  

Net income (loss)

$

1,557,813

$

(3,352,884)

$

5,357,761

$

(2,032,003)

Net income (loss) attributable to Class A common stock subject to possible redemption

$

1,557,813

$

(3,352,884)

$

5,357,761

$

(2,032,003)

Denominator: Weighted average Class A common stock subject to possible redemption

Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption

31,050,000

31,050,000

31,050,000

26,102,473

Basic and diluted net income (loss) per share, Class A Common Stock subject to possible redemption

$

0.05

$

(0.11)

$

0.17

$

(0.08)

Non-Redeemable Class B Common Stock

Numerator: Net income (loss) attributable to Class B common stock

Net income (loss)

$

389,453

$

(838,221)

1,339,440

$

(591,729)

Non-redeemable net income (loss)

$

389,453

$

(838,221)

$

1,339,440

$

(591,729)

Denominator: Weighted average shares of non-redeemable Class B common stock

Basic and diluted weighted average shares outstanding, non-redeemable Class B common stock

7,762,500

7,762,500

7,762,500

7,601,168

Basic and diluted net income (loss) per share, non-redeemable Class B common stock

$

0.05

$

(0.11)

0.17

$

(0.08)

Schedule of reconciliation of Class A common stock subject to possible redemption

At June 30, 2022 and December 31, 2021, the Class A common stock subject to possible redemption reflected in the condensed balance sheets is reconciled in the following table:

Gross proceeds from initial public offering

    

$

310,500,000

Less:

 

  

Proceeds allocated to public warrants

 

(7,555,500)

Offering costs allocated to Class A common stock subject to possible redemption

 

(17,074,803)

Add:

 

  

Remeasurement on Class A common stock subject to possible redemption amount

 

24,630,303

Class A common stock subject to possible redemption

$

310,500,000

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2022
FAIR VALUE MEASUREMENTS  
Schedule of Company's assets that are measured at fair value on a recurring basis

    

June 30, 2022 (unaudited)

    

(Level 1)

    

(Level 2)

    

(Level 3)

Assets

 

  

 

  

 

  

Cash and marketable securities held in Trust Account

$

310,780,579

$

$

Liabilities

 

 

  

 

  

Public Warrants

$

931,500

$

$

Private Placement Warrants

$

$

$

492,600

    

December 31, 2021

    

(Level 1)

    

(Level 2)

    

(Level 3)

Assets

  

  

  

Cash and marketable securities held in Trust Account

$

310,544,829

$

$

Liabilities

 

 

  

 

  

Public Warrants

$

5,589,000

$

$

Private Placement Warrants

$

$

$

2,955,600

Schedule of quantitative information regarding fair value measurements inputs

June 30, 

December 31, 

Input

    

2022

    

2021

Common stock price

$

9.81

$

9.75

Exercise price

$

11.50

$

11.50

Risk-free rate of interest

 

2.97

%

1.34

%

Volatility

 

6.31

%

9.10

%

Term

 

5.51

6.00

Warrant to buy one share (unadjusted for the probability of dissolution)

$

0.60

$

0.54

Warrant to buy one share (adjusted for the probability of dissolution)

$

0.09

$

0.54

Dividend yield

0.00

%

0.00

%

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details)
6 Months Ended
Jan. 28, 2021
USD ($)
$ / shares
shares
Oct. 29, 2020
USD ($)
Jun. 30, 2022
USD ($)
D
$ / shares
shares
Jun. 30, 2021
USD ($)
May 27, 2022
USD ($)
Dec. 31, 2021
USD ($)
Subsidiary, Sale of Stock [Line Items]            
Issue price per unit | $ / shares $ 10.00   $ 10.00      
Sale of private placement warrants (in shares) | shares     15,823,333      
Proceeds from the sale of Private Placements Warrants       $ 8,210,000    
Transaction costs $ 17,495,500          
Underwriting fees 6,210,000          
Deferred underwriting fee payable 10,867,500   $ 10,867,500     $ 10,867,500
Other offering costs 418,000          
Cash held outside the trust account 2,300,000   $ 511,761     346,319
Aggregate proceeds held in trust account $ 310,500,000          
Maturity days of funds in the trust account     185 days      
Obligation to redeem public shares if entity does not complete a business combination (as a percent)     100.00%      
Threshold minimum aggregate fair market value as percentage of assets held in trust account     80.00%      
Redemption of shares calculated based on business days prior to consummation of business combination (in days) | D     2      
Minimum net tangible assets upon consummation of business combination     $ 5,000,001      
Number of days to redeem shares if business combination is not completed by specified date     10 days      
Maximum interest to pay dissolution expenses     $ 100,000      
Working capital deficit     1,483,572      
Related party note payable           0
Initial Public Offering            
Subsidiary, Sale of Stock [Line Items]            
Number of units sold | shares 31,050,000          
Issue price per unit | $ / shares $ 10.00          
Proceeds from issuance initial public offering $ 310,500,000          
Private Placement | Private Placement Warrants            
Subsidiary, Sale of Stock [Line Items]            
Sale of private placement warrants (in shares) | shares 5,473,333          
Price of warrant | $ / shares $ 1.50          
Proceeds from the sale of Private Placements Warrants $ 8,210,000          
Over-allotment option            
Subsidiary, Sale of Stock [Line Items]            
Number of units sold | shares 4,050,000          
Promissory Note with Related Party            
Subsidiary, Sale of Stock [Line Items]            
Maximum borrowing capacity of related party promissory note   $ 300,000        
Related party note payable $ 300,000          
Working Capital Loan            
Subsidiary, Sale of Stock [Line Items]            
Maximum borrowing capacity of related party promissory note         $ 750,000  
Related party note payable     $ 750,000     $ 0
Class B Common Stock | Sponsor | Founder Shares            
Subsidiary, Sale of Stock [Line Items]            
Aggregate purchase price   $ 25,000        
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Company's Condensed Statements of Cash Flows (Details) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash Flows from Operating Activities:    
Warrant issuance costs   $ 420,743
Net cash used in operating activities $ (584,558) (873,233)
Cash Flows From Financing Activities:    
Proceeds from sale of Units, net of underwriting discounts paid   304,290,000
Net cash provided by financing activities $ 750,000 312,221,955
As Previously Reported    
Cash Flows from Operating Activities:    
Net cash used in operating activities   (1,293,976)
Cash Flows From Financing Activities:    
Proceeds from sale of Units, net of underwriting discounts paid   304,710,744
Net cash provided by financing activities   $ 312,642,698
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
Offering costs charged to shareholders' equity $ 17,100,000  
Offering costs related to warrant liabilities 400,000  
Unrecognized tax benefits 0 $ 0
Unrecognized tax benefits accrued for interest and penalties $ 0 0
Shares excluded from calculation of diluted income per share 15,823,333  
Federal depository insurance coverage $ 250,000  
Number of warrants to purchase shares issued 15,823,333  
Related party note payable   $ 0
Debt Discount $ 0  
Proceeds $ 0  
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net income per common share (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Numerator: Income (loss) attributable to Class A Common Stock subject to possible redemption            
Net income (loss) $ 1,947,266 $ 4,749,935 $ (4,191,105) $ 1,567,374 $ 6,697,201 $ (2,623,732)
Class A Common Stock Subject to Redemption            
Numerator: Income (loss) attributable to Class A Common Stock subject to possible redemption            
Net income (loss) 1,557,813   (3,352,884)   5,357,761 (2,032,003)
Net income (loss) attributable to Class A common stock subject to possible redemption $ 1,557,813   $ (3,352,884)   $ 5,357,761 $ (2,032,003)
Denominator: Weighted average Class of common stock            
Basic weighted average shares outstanding 31,050,000   31,050,000   31,050,000 26,102,473
Diluted weighted average shares outstanding 31,050,000   31,050,000   31,050,000 26,102,473
Basic net income (loss) per share $ 0.05   $ (0.11)   $ 0.17 $ (0.08)
Diluted net income (loss) per share $ 0.05   $ (0.11)   $ 0.17 $ (0.08)
Non redeemable Class B common stock            
Numerator: Income (loss) attributable to Class A Common Stock subject to possible redemption            
Net income (loss) $ 389,453   $ (838,221)   $ 1,339,440 $ (591,729)
Non-redeemable net income (loss) $ 389,453   $ (838,221)   $ 1,339,440 $ (591,729)
Denominator: Weighted average Class of common stock            
Basic weighted average shares outstanding 7,762,500   7,762,500   7,762,500 7,601,168
Diluted weighted average shares outstanding 7,762,500   7,762,500   7,762,500 7,601,168
Basic net income (loss) per share $ 0.05   $ (0.11)   $ 0.17 $ (0.08)
Diluted net income (loss) per share $ 0.05   $ (0.11)   $ 0.17 $ (0.08)
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption (Details) - Class A Common Stock Subject to Redemption - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Gross proceeds from initial public offering $ 310,500,000 $ 310,500,000
Proceeds allocated to public warrants (7,555,500) (7,555,500)
Offering costs allocated to Class A common stock subject to possible redemption (17,074,803) (17,074,803)
Remeasurement on Class A common stock subject to possible redemption amount 24,630,303 24,630,303
Class A common stock subject to possible redemption $ 310,500,000 $ 310,500,000
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
INITIAL PUBLIC OFFERING (Details) - $ / shares
Jan. 28, 2021
Jun. 30, 2022
Subsidiary, Sale of Stock [Line Items]    
Issue price per unit $ 10.00 $ 10.00
Initial Public Offering    
Subsidiary, Sale of Stock [Line Items]    
Number of units sold 31,050,000  
Issue price per unit $ 10.00  
Initial Public Offering | Class A Common Stock    
Subsidiary, Sale of Stock [Line Items]    
Number of shares in a unit 1  
Initial Public Offering | Public Warrants    
Subsidiary, Sale of Stock [Line Items]    
Number of warrants in a unit 0.33  
Exercise price of warrants $ 11.50  
Initial Public Offering | Public Warrants | Class A Common Stock    
Subsidiary, Sale of Stock [Line Items]    
Number of shares issuable per warrant 1  
Over-allotment option    
Subsidiary, Sale of Stock [Line Items]    
Number of units sold 4,050,000  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
PRIVATE PLACEMENT (Details) - USD ($)
6 Months Ended
Jan. 28, 2021
Jun. 30, 2021
Jun. 30, 2022
Subsidiary, Sale of Stock [Line Items]      
Number of warrants to purchase shares issued     15,823,333
Aggregate purchase price   $ 8,210,000  
Private Placement | Private Placement Warrants      
Subsidiary, Sale of Stock [Line Items]      
Number of warrants to purchase shares issued 5,473,333    
Price of warrants $ 1.50    
Aggregate purchase price $ 8,210,000    
Exercise price of warrant $ 11.50    
Amount held in the trust account from private placement warrants issuance proceeds $ 6,210,000    
Private Placement | Private Placement Warrants | Class A Common Stock      
Subsidiary, Sale of Stock [Line Items]      
Number of shares per warrant 1    
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS - Founder Shares (Details) - Founder Shares - Sponsor - Class B Common Stock
6 Months Ended
Jan. 25, 2021
shares
Oct. 29, 2020
USD ($)
shares
Jun. 30, 2022
D
$ / shares
Related Party Transaction [Line Items]      
Number of shares issued   6,468,750  
Aggregate purchase price | $   $ 25,000  
Share dividend 1,293,750    
Aggregate number of shares owned 7,762,500    
Restrictions on transfer period of time after business combination completion     1 year
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares     $ 12.00
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D     20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D     30
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences     150 days
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS - Additional Information (Details) - USD ($)
6 Months Ended
Jun. 30, 2022
May 27, 2022
Dec. 31, 2021
Jan. 28, 2021
Oct. 29, 2020
Related Party Transaction [Line Items]          
Related party note payable     $ 0    
Promissory Note with Related Party          
Related Party Transaction [Line Items]          
Maximum borrowing capacity of related party promissory note         $ 300,000
Related party note payable       $ 300,000  
Related Party Loans          
Related Party Transaction [Line Items]          
Related party payables $ 19,244   250,000    
Working Capital Loan          
Related Party Transaction [Line Items]          
Maximum borrowing capacity of related party promissory note   $ 750,000      
Related party note payable $ 750,000   $ 0    
Working Capital Loan | Working capital loans warrant          
Related Party Transaction [Line Items]          
Price of warrant $ 1.50        
Administrative Services Agreement          
Related Party Transaction [Line Items]          
Expenses per month $ 10,000        
Amount accrued or paid $ 0        
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details)
Jun. 30, 2022
USD ($)
item
$ / shares
Dec. 31, 2021
USD ($)
Jan. 28, 2021
USD ($)
COMMITMENTS AND CONTINGENCIES      
Number of demands securities are entitled to | item 3    
Deferred fee per unit | $ / shares $ 0.35    
Deferred underwriting fee payable | $ $ 10,867,500 $ 10,867,500 $ 10,867,500
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' DEFICIT - Preferred Stock Shares (Details) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
STOCKHOLDERS' DEFICIT    
Preferred shares, shares authorized 1,000,000 1,000,000
Preferred stock, par value, (per share) $ 0.0001 $ 0.0001
Preferred shares, shares issued 0 0
Preferred shares, shares outstanding 0 0
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' DEFICIT - Common Stock Shares (Details)
6 Months Ended
Jun. 30, 2022
Vote
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
Class of Stock [Line Items]    
Class B common stock conversion ratio to Class B 1  
Class A Common Stock    
Class of Stock [Line Items]    
Common shares, shares authorized (in shares) 400,000,000 400,000,000
Common shares, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001
Common shares, shares issued (in shares) 0 0
Common shares, shares outstanding (in shares) 0 0
Class A Common Stock Subject to Redemption    
Class of Stock [Line Items]    
Class A common stock subject to possible redemption, outstanding (in shares) 31,050,000 31,050,000
Class A Common Stock Not Subject to Redemption    
Class of Stock [Line Items]    
Common shares, votes per share | Vote 1  
Common shares, shares issued (in shares) 0 0
Common shares, shares outstanding (in shares) 0 0
Class B Common Stock    
Class of Stock [Line Items]    
Common shares, shares authorized (in shares) 40,000,000 40,000,000
Common shares, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001
Common shares, votes per share | Vote 1  
Common shares, shares issued (in shares) 7,762,500 7,762,500
Common shares, shares outstanding (in shares) 7,762,500 7,762,500
Ratio to be applied to the stock in the conversion 20  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
WARRANTS (Details)
6 Months Ended
Jun. 30, 2022
USD ($)
item
D
$ / shares
Dec. 31, 2021
USD ($)
Jan. 28, 2021
USD ($)
Class of Warrant or Right [Line Items]      
Fair value of warrant liabilities | $ $ 1,424,100 $ 8,544,600 $ 11,600,000
Public Warrants      
Class of Warrant or Right [Line Items]      
Public Warrants exercisable term after the completion of a business combination 30 days    
Public Warrants exercisable term from the closing of the initial public offering 12 months    
Public Warrants expiration term 5 years    
Threshold issue price per share $ 9.20    
Adjustment of exercise price of warrants based on market value and newly issued price (as a percent) 115.00%    
Adjustment of redemption price of stock based on market value and newly issued price (as a percent) 180.00%    
Maximum period after business combination in which to file registration statement 15 days    
Maximum threshold period for registration statement to become effective after business combination 60 days    
Public Warrants | Class A Common Stock      
Class of Warrant or Right [Line Items]      
Threshold issue price per share $ 9.20    
Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant 60.00%    
Trading period after business combination used to measure dilution of warrant | D 20    
Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00      
Class of Warrant or Right [Line Items]      
Stock price trigger for redemption of public warrants (in dollars per share) $ 18.00    
Redemption price per warrant (in dollars per share) $ 0.01    
Threshold trading days for redemption of public warrants | item 20    
Threshold consecutive trading days for redemption of public warrants | D 30    
Minimum threshold written notice period for redemption of public warrants 30 days    
Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00      
Class of Warrant or Right [Line Items]      
Stock price trigger for redemption of public warrants (in dollars per share) $ 10.00    
Redemption price per warrant (in dollars per share) $ 0.10    
Minimum threshold written notice period for redemption of public warrants 30 days    
Private Placement Warrants      
Class of Warrant or Right [Line Items]      
Restrictions on transfer period of time after business combination completion 30 days    
Public And Private Placement Warrants      
Class of Warrant or Right [Line Items]      
Fair value of warrant liabilities | $ $ 1,424,100 $ 8,544,600  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Jan. 28, 2021
Assets:      
Cash and marketable securities held in Trust Account $ 310,780,579 $ 310,544,829  
Liabilities:      
Warrant liability 1,424,100 8,544,600 $ 11,600,000
Level 1 | Recurring      
Assets:      
Cash and marketable securities held in Trust Account 310,780,579 310,544,829  
Level 1 | Recurring | Public Warrants      
Liabilities:      
Warrant liability 931,500    
Level 1 | Recurring | Private Placement Warrants      
Liabilities:      
Warrant liability   5,589,000  
Level 2 | Recurring      
Assets:      
Cash and marketable securities held in Trust Account   0  
Level 2 | Recurring | Private Placement Warrants      
Liabilities:      
Warrant liability   0  
Level 3 | Recurring | Private Placement Warrants      
Liabilities:      
Warrant liability $ 492,600 $ 2,955,600  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS - Fair Value Measurements Inputs (Details) - Private Placement Warrants
Jun. 30, 2022
Dec. 31, 2021
Common stock price    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 9.81 9.75
Exercise price    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 11.50 11.50
Risk-free rate of interest    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 2.97 1.34
Volatility    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 6.31 9.10
Term    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 5.51 6.00
Warrant to buy one share (unadjusted for the probability of dissolution)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 0.60 0.54
Warrant to buy one share (adjusted for the probability of dissolution)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 0.09 0.54
Dividend yield    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 0.00 0.00
XML 49 ssaau-20220630x10q_htm.xml IDEA: XBRL DOCUMENT 0001830547 ssaau:PublicWarrantsMember 2022-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember us-gaap:CommonStockMember 2022-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember us-gaap:CommonStockMember 2022-03-31 0001830547 ssaau:CommonClassaSubjectToRedemptionMember us-gaap:CommonStockMember 2021-12-31 0001830547 ssaau:CommonClassaSubjectToRedemptionMember us-gaap:CommonStockMember 2021-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember us-gaap:CommonStockMember 2021-03-31 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2022-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2021-12-31 0001830547 ssaau:FounderSharesMember ssaau:SponsorMember us-gaap:CommonClassBMember 2020-10-29 2020-10-29 0001830547 us-gaap:RetainedEarningsMember 2022-06-30 0001830547 us-gaap:RetainedEarningsMember 2022-03-31 0001830547 2022-03-31 0001830547 us-gaap:RetainedEarningsMember 2021-12-31 0001830547 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001830547 us-gaap:RetainedEarningsMember 2021-06-30 0001830547 us-gaap:RetainedEarningsMember 2021-03-31 0001830547 2021-03-31 0001830547 us-gaap:RetainedEarningsMember 2020-12-31 0001830547 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001830547 ssaau:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001830547 ssaau:PublicAndPrivatePlacementWarrantsMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001830547 ssaau:PublicAndPrivatePlacementWarrantsMember 2021-12-31 0001830547 us-gaap:IPOMember 2021-01-28 0001830547 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001830547 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001830547 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001830547 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-06-30 0001830547 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-03-31 0001830547 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-12-31 0001830547 ssaau:WorkingCapitalLoanMember 2022-06-30 0001830547 ssaau:WorkingCapitalLoanMember 2021-12-31 0001830547 ssaau:PromissoryNoteWithRelatedPartyMember 2021-01-28 0001830547 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001830547 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001830547 2022-01-01 2022-03-31 0001830547 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001830547 ssaau:NonRedeemableClassBCommonStockMember 2022-04-01 2022-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2022-04-01 2022-06-30 0001830547 ssaau:NonRedeemableClassBCommonStockMember 2022-01-01 2022-06-30 0001830547 ssaau:NonRedeemableClassBCommonStockMember 2021-04-01 2021-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2021-04-01 2021-06-30 0001830547 ssaau:NonRedeemableClassBCommonStockMember 2021-01-01 2021-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2021-01-01 2021-06-30 0001830547 ssaau:RelatedPartyLoansMember 2022-06-30 0001830547 ssaau:RelatedPartyLoansMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember ssaau:WarrantToBuyOneShareUnadjustedForProbabilityOfDissolutionMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember ssaau:WarrantToBuyOneShareAdjustedForProbabilityOfDissolutionMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember ssaau:WarrantToBuyOneShareUnadjustedForProbabilityOfDissolutionMember 2021-12-31 0001830547 ssaau:PrivatePlacementWarrantsMember ssaau:WarrantToBuyOneShareAdjustedForProbabilityOfDissolutionMember 2021-12-31 0001830547 2022-04-01 2022-06-30 0001830547 2021-04-01 2021-06-30 0001830547 ssaau:CommonClassaNotSubjectToRedemptionMember 2021-12-31 0001830547 us-gaap:CommonClassAMember 2022-06-30 0001830547 us-gaap:CommonClassBMember 2021-12-31 0001830547 us-gaap:CommonClassAMember 2021-12-31 0001830547 ssaau:FounderSharesMember ssaau:SponsorMember us-gaap:CommonClassBMember 2021-01-25 2021-01-25 0001830547 ssaau:PublicWarrantsMember us-gaap:CommonClassAMember us-gaap:IPOMember 2021-01-28 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2021-01-28 0001830547 ssaau:PublicWarrantsMember us-gaap:IPOMember 2021-01-28 0001830547 2021-06-30 0001830547 2020-12-31 0001830547 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001830547 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001830547 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001830547 us-gaap:OverAllotmentOptionMember 2021-01-28 2021-01-28 0001830547 us-gaap:IPOMember 2021-01-28 2021-01-28 0001830547 ssaau:CommonClassaSubjectToRedemptionMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2022-01-01 2022-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2021-01-01 2021-12-31 0001830547 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001830547 ssaau:FounderSharesMember ssaau:SponsorMember us-gaap:CommonClassBMember 2022-01-01 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember 2022-01-01 2022-06-30 0001830547 ssaau:AdministrativeServicesAgreementMember 2022-01-01 2022-06-30 0001830547 ssaau:PublicWarrantsMember us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001830547 ssaau:PublicWarrantsMember us-gaap:IPOMember 2021-01-28 2021-01-28 0001830547 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-01-28 2021-01-28 0001830547 srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-06-30 0001830547 ssaau:WorkingCapitalLoanMember 2022-05-27 0001830547 ssaau:PromissoryNoteWithRelatedPartyMember 2020-10-29 0001830547 2021-01-28 0001830547 2021-01-01 2021-06-30 0001830547 us-gaap:CommonClassBMember 2022-01-01 2022-06-30 0001830547 us-gaap:CommonClassBMember 2022-06-30 0001830547 ssaau:CommonClassaNotSubjectToRedemptionMember 2022-06-30 0001830547 ssaau:WorkingCapitalLoansWarrantMember ssaau:WorkingCapitalLoanMember 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2021-01-28 0001830547 ssaau:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member ssaau:PublicWarrantsMember 2022-01-01 2022-06-30 0001830547 ssaau:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member ssaau:PublicWarrantsMember 2022-01-01 2022-06-30 0001830547 ssaau:PublicWarrantsMember 2022-01-01 2022-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2021-01-28 2021-01-28 0001830547 ssaau:AdministrativeServicesAgreementMember 2022-06-30 0001830547 2021-01-28 2021-01-28 0001830547 ssaau:FounderSharesMember ssaau:SponsorMember us-gaap:CommonClassBMember 2021-01-25 0001830547 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001830547 2021-01-01 2021-03-31 0001830547 2022-06-30 0001830547 2021-12-31 0001830547 us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001830547 ssaau:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember 2022-01-01 2022-06-30 0001830547 ssaau:UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember 2022-01-01 2022-06-30 0001830547 us-gaap:CommonClassBMember 2022-08-17 0001830547 us-gaap:CommonClassAMember 2022-08-17 0001830547 2022-01-01 2022-06-30 shares iso4217:USD pure iso4217:USD shares ssaau:D ssaau:item ssaau:Vote 31050000 31050000 31050000 26102473 0.05 -0.11 0.17 -0.08 7762500 7762500 7762500 7601168 0.05 -0.11 0.17 -0.08 0001830547 --12-31 2022 Q2 false 31050000 31050000 31050000 26102473 0.05 -0.11 0.17 -0.08 7762500 7762500 7762500 7601168 0.05 -0.11 0.17 -0.08 0 0 0.33 0 0 0 0 7762500 7762500 310500000 -7555500 -17074803 24630303 310500000 0 0 7762500 7762500 10-Q true 2022-06-30 false 001-39930 Science Strategic Acquisition Corp. Alpha DE 85-3594633 1447 2nd Street Santa Monica CA 90401 310 393-3024 Units, each consisting of one share of Class A common stock, $0.0001 par value, and one-third of one redeemable warrant SSAAU NASDAQ Class A common stock SSAA NASDAQ Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 SSAAW NASDAQ Yes Yes Non-accelerated Filer true true false true 31050000 7762500 511761 346319 239075 337104 750836 683423 310780579 310544829 0 27689 310780579 310572518 311531415 311255941 0 70000 19244 250000 750000 0 1565164 1315635 2334408 1635635 1424100 8544600 10867500 10867500 12291600 19412100 14626008 21047735 31050000 31050000 310500000 310500000 0.0001 0.0001 1000000 1000000 0 0 0 0 0.0001 0.0001 400000000 400000000 0 0 31050000 31050000 0 0 0.0001 0.0001 40000000 40000000 7762500 7762500 776 776 0 0 -13595369 -20292570 -13594593 -20291794 311531415 311255941 341179 211844 659049 729474 -341179 -211844 -659049 -729474 231412 6774 235750 34744 -2057033 3986035 -7120500 1929002 2288445 -3979261 7356250 -1894258 1947266 -4191105 6697201 -2623732 31050000 31050000 31050000 26102473 0.05 -0.11 0.17 -0.08 7762500 7762500 7762500 7601168 0.05 -0.11 0.17 -0.08 31050000 310500000 7762500 776 0 -20292570 -20291794 4749935 4749935 31050000 310500000 7762500 776 -15542635 -15541859 1947266 1947266 31050000 310500000 7762500 776 -13595369 -13594593 7762500 776 24224 -5000 20000 31050000 31050000 285869697 4159734 4159734 24630303 4183958 20446345 24630303 1567374 1567374 31050000 310500000 7762500 776 -18883971 -18883195 -4191105 -4191105 31050000 310500000 7762500 776 -23075076 -23074300 6697201 -2623732 235750 34744 -7120500 1929002 420743 -125718 566520 -230756 -70000 249529 2018 -584558 -873233 310500000 -310500000 304290000 8210000 300000 300000 750000 278045 750000 312221955 165442 848722 346319 20000 511761 868722 285869697 24630303 11605766 135000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 1. ORGANIZATION AND PLANS OF BUSINESS OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Organization and General</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Science Strategic Acquisition Corp. Alpha (the “Company”) was incorporated in Delaware on October 22, 2020. The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”). The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsor and Initial Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2022, the Company had not commenced any operations. All activity through June 30, 2022 relates to the Company’s formation, the initial public offering (the “Initial Public Offering”), which is described below, and identifying a target for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering, and non-operating income or expenses from the change in fair value of warrant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration statements for the Initial Public Offering were declared effective on January 25, 2021. On January 28, 2021, the Company consummated the Initial Public Offering of 31,050,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), which includes the exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at $10.00 per Unit, generating gross proceeds of $310,500,000, which is described in Note 4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,473,333 warrants (each, a “Private Placement Warrant” and, collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to SSAC Alpha Sponsor, LLC (the “Sponsor”), generating gross proceeds of $8,210,000, which is described in Note 5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transaction costs amounted to $17,495,500, consisting of $6,210,000 of underwriting fees, $10,867,500 of deferred underwriting fees and $418,000 of other offering costs. In addition, cash of approximately $2,300,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the Initial Public Offering on January 28, 2021, an amount of $310,500,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”). The funds in the Trust Account will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended. The Company will not be permitted to withdraw any of the principal or interest held in the Trust Account except for the withdrawal of interest to pay taxes, if any. The funds held in the Trust Account will not otherwise be released from the trust account until the earliest of: (1) the Company’s completion of a Business Combination; (2) the redemption of any Public Shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete a Business Combination on or before January 28, 2023 or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity; and (3) the redemption of the Company’s Public Shares if the Company has not completed a Business Combination on or before January 28, 2023, subject to applicable law. Based on current interest rates, the Company expects that interest earned on the Trust Account will be sufficient to pay taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s management has broad discretion with respect to the specific application of the net proceeds from the Initial Public Offering, although substantially all of the net proceeds from the Initial Public Offering are intended to be generally applied toward consummating a Business Combination with (or acquisition of) a Target Business. As used herein, “Target Business” means one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the Trust Account (excluding taxes payable on the interest earned on the Trust Account) at the time of the signing of a definitive agreement in connection with a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully effect a Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will provide its public stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination, either (i) in connection with a stockholder meeting called to approve such Business Combination or (ii) by means of a tender offer. The public stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account, calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to the public stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 7). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decision as to whether the Company will seek stockholder approval of a Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, in its sole discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval unless a vote is required by law or stock exchange listing requirements. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the shares of common stock voted are voted in favor of a Business Combination. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 upon consummation of a Business Combination. In such case, the Company would not proceed with the redemption of its Public Shares and the related Business Combination, and instead may search for an alternate Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will have until January 28, 2023 to complete its initial Business Combination. If the Company does not complete a Business Combination by such date (or such longer period as provided in an amendment to the Company’s amended and restated certificate of incorporation approved by its stockholders (an “Extension Period”)), it shall (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. The initial stockholders have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares (as defined in Note 6) if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. However, if the initial stockholders acquire Public Shares, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to have all third parties, including, but not limited to, all vendors, service providers (other than its independent registered public accounting firm), prospective target businesses and other entities with which the Company does business execute agreements with the Company waiving any right, title, interest or claims of any kind in or to any monies held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity, Capital Resources and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2022, the Company had $511,761 in cash held outside of the Trust Account and a working capital deficit of $1,483,572.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor to cover certain offering costs on the Company’s behalf in exchange for the issuance of Founder Shares (as discussed in Note 6), and a loan from the Sponsor of $300,000 under the Promissory Note (as discussed in Note 6). The Company repaid the Promissory Note in full on February 2, 2021. Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the private placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Sponsor may provide up to $750,000 to the Company as a working capital loan (the “Working Capital Loan”) (as discussed in Note 6). As of June 30, 2022 and December 31, 2021, there was $750,000 and $0 outstanding under the Working Capital Loan, respectively. In order to fund working capital deficiencies or finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s directors and officers may, but are not obligated to, loan the Company additional funds (“Additional Working Capital Loans”) as may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has incurred and expects to incur significant costs in pursuit of its financing and acquisition plans. Management believes that the Company has access to funds from the Sponsor that are sufficient to fund the working capital needs of the Company until the consummation of an initial Business Combination or for a minimum of one year from the date of issuance of these financial statements. However, in connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Company’s cash flow deficit and the liquidation date of January 28, 2023 being within twelve months from the issuance of these financial statements raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. There is no assurance that the Company’s plans to consummate a Business Combination or raise additional funds will be successful. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 31050000 4050000 10.00 310500000 5473333 1.50 8210000 17495500 6210000 10867500 418000 2300000 310500000 10.00 P185D 1 0.80 2 5000001 P10D 100000 10.00 511761 1483572 25000 300000 750000 750000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 2. REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In connection with the preparation of the Company's financial statements as of June 30, 2022, management identified an error made in its historical financial statements where, warrant issuance costs were incorrectly included within the financing activities section of the Statement of Cash Flows as of June 30, 2021. The Company revised the Condensed Statements of Cash Flows by reclassifying warrant issuance costs from financing activities to operating activities for the six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The impact of the revision on the Company’s Condensed Statements of Cash Flows is reflected in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Previously Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Revised</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows Used in Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Warrant issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420,743</p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,293,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (873,233)</p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows From Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Proceeds from sale of Units, net of underwriting discounts paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,710,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,290,000</p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 312,642,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 312,221,955</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">There is no impact to the reported amounts for total assets, total liabilities, or net income.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The impact of the revision on the Company’s Condensed Statements of Cash Flows is reflected in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Previously Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Revised</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows Used in Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Warrant issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420,743</p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,293,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (873,233)</p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows From Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Proceeds from sale of Units, net of underwriting discounts paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,710,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,290,000</p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 312,642,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 312,221,955</p></td></tr></table> 420743 -1293976 -873233 304710744 304290000 312642698 312221955 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on April 12, 2022, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2021 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2022 and December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Marketable Securities Held in Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At June 30, 2022, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities. Through June 30, 2022, the Company has not withdrawn any monies from the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The provision for income taxes was deemed to be de minimis for the three and six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Net Income (Loss) per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt;">Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period in compliance with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings per Share.” The remeasurement associated with the redeemable Class A common stock is excluded from net income (loss) per share as the redemption value approximates fair value. The Company has not considered the effect of the warrants sold in the Initial Public Offering </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted net income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">The Company’s condensed statement of operations includes a presentation of net income (loss) per share of Class A common stock subject to possible redemption and non-redeemable Class B common stock and allocates the net income (loss) into the two classes of stock in calculating net income (loss). Net income (loss) per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class A common stock subject to possible redemption outstanding. Net income (loss) per share, basic and diluted, for Class B non-redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class B non-redeemable common stock outstanding for the period. As of June 30, 2022 and June 30, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercisable or converted to shares of common stock and then share in the earnings of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Class A common stock subject to possible redemption</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator: Net income (loss) attributable to Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,557,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,352,884)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,357,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,032,003)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) attributable to Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,557,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,352,884)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,357,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,032,003)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,102,473</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net income (loss) per share, Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_uMiFu3yLk0u3a10QV6uBfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PdsB5CsZa0iOBOgS1g6SVg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_BZ2XTqGQvUy8k0yDzoV7GQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bUCNQYuB1UaGRqwyFA1xCg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Non-Redeemable Class B Common Stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator: Net income (loss) attributable to Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (838,221)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,339,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (591,729)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Non-redeemable net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (838,221)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,339,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (591,729)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average shares of non-redeemable Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares outstanding, non-redeemable Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,762,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,762,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,762,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,601,168</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net income (loss) per share, non-redeemable Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_jgdoWNt7vkus9_sXkkWpxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_QRtXRUZnjk-u6Ww_Mhnrgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pPqHlomb4UqWrCYPhFWmWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the price that would be received for sale of an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and</span><span style="display:inline-block;width:0pt;"/></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span><span style="display:inline-block;width:0pt;"/></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Warrants Exercisable for Class A Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, “Derivatives and Hedging” (“ASC 815”). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Working Capital Loan Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounted for the Working Capital Loan payable in accordance with ASC 470, “Debt”. The Working Capital Loan payable is recorded at amortized cost. The conversion option feature had a fair value of $0 as of on June 1, 2022, the date of initial measurement. As such, there is no debt discount recorded as there are no proceeds to allocate to the conversion option feature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Class A Common Stock Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Such changes are reflected in additional paid-in capital to the extent available, or in the absence of additional capital, in accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">At June 30, 2022 and December 31, 2021, the Class A common stock subject to possible redemption reflected in the condensed balance sheets is reconciled in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds from initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_s2mZab48WEaXSiwyCIE2Fg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds allocated to public warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,555,500)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Offering costs allocated to Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,074,803)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remeasurement on Class A common stock subject to possible redemption amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,630,303</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_j1X5V_hKlEy5c3l4LHIArw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 310,500,000</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">In August 2020, FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on April 12, 2022, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2021 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2022 and December 31, 2021.</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.</p> 17100000 400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Marketable Securities Held in Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At June 30, 2022, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities. Through June 30, 2022, the Company has not withdrawn any monies from the Trust Account.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. The provision for income taxes was deemed to be de minimis for the three and six months ended June 30, 2022.</p> 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Net Income (Loss) per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt;">Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period in compliance with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings per Share.” The remeasurement associated with the redeemable Class A common stock is excluded from net income (loss) per share as the redemption value approximates fair value. The Company has not considered the effect of the warrants sold in the Initial Public Offering </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted net income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">The Company’s condensed statement of operations includes a presentation of net income (loss) per share of Class A common stock subject to possible redemption and non-redeemable Class B common stock and allocates the net income (loss) into the two classes of stock in calculating net income (loss). Net income (loss) per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class A common stock subject to possible redemption outstanding. Net income (loss) per share, basic and diluted, for Class B non-redeemable common stock is calculated by dividing the net income (loss) by the weighted average number of Class B non-redeemable common stock outstanding for the period. As of June 30, 2022 and June 30, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercisable or converted to shares of common stock and then share in the earnings of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Class A common stock subject to possible redemption</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator: Net income (loss) attributable to Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,557,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,352,884)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,357,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,032,003)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) attributable to Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,557,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,352,884)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,357,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,032,003)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,102,473</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net income (loss) per share, Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_uMiFu3yLk0u3a10QV6uBfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PdsB5CsZa0iOBOgS1g6SVg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_BZ2XTqGQvUy8k0yDzoV7GQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bUCNQYuB1UaGRqwyFA1xCg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Non-Redeemable Class B Common Stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator: Net income (loss) attributable to Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (838,221)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,339,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (591,729)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Non-redeemable net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (838,221)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,339,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (591,729)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average shares of non-redeemable Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares outstanding, non-redeemable Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,762,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,762,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,762,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,601,168</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net income (loss) per share, non-redeemable Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_jgdoWNt7vkus9_sXkkWpxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_QRtXRUZnjk-u6Ww_Mhnrgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pPqHlomb4UqWrCYPhFWmWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td></tr></table> 15823333 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net income (loss) per common share (in dollars, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Class A common stock subject to possible redemption</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator: Net income (loss) attributable to Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,557,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,352,884)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,357,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,032,003)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) attributable to Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,557,813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,352,884)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,357,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,032,003)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,050,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,102,473</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net income (loss) per share, Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_uMiFu3yLk0u3a10QV6uBfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PdsB5CsZa0iOBOgS1g6SVg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_BZ2XTqGQvUy8k0yDzoV7GQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bUCNQYuB1UaGRqwyFA1xCg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Non-Redeemable Class B Common Stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator: Net income (loss) attributable to Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (838,221)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,339,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (591,729)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Non-redeemable net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (838,221)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,339,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (591,729)</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average shares of non-redeemable Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares outstanding, non-redeemable Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,762,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,762,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,762,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,601,168</p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net income (loss) per share, non-redeemable Class B common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_jgdoWNt7vkus9_sXkkWpxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_QRtXRUZnjk-u6Ww_Mhnrgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pPqHlomb4UqWrCYPhFWmWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td></tr></table> 1557813 -3352884 5357761 -2032003 1557813 -3352884 5357761 -2032003 31050000 31050000 31050000 26102473 0.05 -0.11 0.17 -0.08 389453 -838221 1339440 -591729 389453 -838221 1339440 -591729 7762500 7762500 7762500 7601168 0.05 -0.11 0.17 -0.08 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p> 250000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the price that would be received for sale of an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and</span><span style="display:inline-block;width:0pt;"/></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span><span style="display:inline-block;width:0pt;"/></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Warrants Exercisable for Class A Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, “Derivatives and Hedging” (“ASC 815”). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> 15823333 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Working Capital Loan Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounted for the Working Capital Loan payable in accordance with ASC 470, “Debt”. The Working Capital Loan payable is recorded at amortized cost. The conversion option feature had a fair value of $0 as of on June 1, 2022, the date of initial measurement. As such, there is no debt discount recorded as there are no proceeds to allocate to the conversion option feature.</p> 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Class A Common Stock Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Such changes are reflected in additional paid-in capital to the extent available, or in the absence of additional capital, in accumulated deficit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">At June 30, 2022 and December 31, 2021, the Class A common stock subject to possible redemption reflected in the condensed balance sheets is reconciled in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds from initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_s2mZab48WEaXSiwyCIE2Fg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds allocated to public warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,555,500)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Offering costs allocated to Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,074,803)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remeasurement on Class A common stock subject to possible redemption amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,630,303</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_j1X5V_hKlEy5c3l4LHIArw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 310,500,000</b></p></td></tr></table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">At June 30, 2022 and December 31, 2021, the Class A common stock subject to possible redemption reflected in the condensed balance sheets is reconciled in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds from initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_s2mZab48WEaXSiwyCIE2Fg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds allocated to public warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,555,500)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Offering costs allocated to Class A common stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,074,803)</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Remeasurement on Class A common stock subject to possible redemption amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,630,303</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common stock subject to possible redemption</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_j1X5V_hKlEy5c3l4LHIArw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 310,500,000</b></p></td></tr></table> 310500000 -7555500 -17074803 24630303 310500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">In August 2020, FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 4. INITIAL PUBLIC OFFERING </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On January 28, 2021, pursuant to the Initial Public Offering, the Company sold 31,050,000 Units, which includes the full exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and <span style="-sec-ix-hidden:Hidden_vwIr208FkkOu_vXg_gJG4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-third of one redeemable warrant (each whole warrant, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment (see Note 9).</p> 31050000 4050000 10.00 1 1 11.50 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 5. PRIVATE PLACEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 5,473,333 Private Placement Warrants, at a price of $1.50 per Private Placement Warrant, for an aggregate purchase price of $8,210,000 in a private placement. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share. $6,210,000 of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination by January 28, 2023 or during any Extension Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.</p> 5473333 1.50 8210000 1 11.50 6210000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 6. RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Founder Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 29, 2020, the Sponsor purchased 6,468,750 shares of Class B common stock for an aggregate purchase price of $25,000. On January 25, 2021, the Company effected a stock dividend of 1,293,750 shares of Class B common stock to holders of Class B common stock on a pro rata basis based on their holdings, resulting in the Company’s initial stockholders holding an aggregate of 7,762,500 shares of Class B common stock (see Note 8). All share and per-share amounts have been retroactively restated to reflect the stock dividend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The initial stockholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Class B common stock or Class A common stock received upon conversion thereof (together, “Founder Shares”) until the earlier of: (A) one year after the completion of a Business Combination; and (B) subsequent to a Business Combination (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of common stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Promissory Note — Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 29, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Promissory Note”). The Promissory Note was non-interest bearing and payable on the earlier of December 31, 2021 or the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $300,000 remained outstanding at the closing of the Initial Public Offering on January 28, 2021. On February 2, 2021, the Company repaid the Promissory Note in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Administrative Services Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company agreed, commencing on the date that securities of the Company were first listed on the Nasdaq Capital Market through the earlier of the Company’s consummation of a Business Combination or its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, administrative and support services. The Company and the affiliate of the Sponsor canceled the Administrative Services Agreement effective March 31, 2022 as the affiliate of the Sponsor agreed to waive the monthly payments. No amounts have been accrued or paid for the period from the commencement date through June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Related Party Payables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company owed $19,244 and $250,000 as of June 30, 2022 and December 31, 2021, respectively, to a related party for certain costs paid by an affiliate of the Sponsor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Working Capital Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On May 27, 2022, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Sponsor may provide up to $750,000 to the Company as a working capital loan. The Working Capital Loan does not bear interest and is repayable in full on the earlier of (i) the consummation of the Company’s initial Business Combination or (ii) end of the Business Combination period. Upon the consummation of a Business Combination, the Sponsor shall have the option, but not the obligation, to convert the principal balance of the Working Capital Loan, in whole or in part, into warrants at a price of $1.50 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loan but no proceeds held in the Trust Account would be used to repay the Working Capital Loan. The Working Capital Loan is subject to customary events of default, the occurrence of which automatically trigger the unpaid principal balance of the Working Capital Loan and all other sums payable with regard to the Working Capital Loan becoming immediately due and payable. As of June 30, 2022 and December 31, 2021, there was $750,000 and $0 outstanding under the Working Capital Loan, respectively. </p> 6468750 25000 1293750 7762500 P1Y 12.00 20 30 P150D 300000 300000 10000 0 19244 250000 750000 1.50 750000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 7. COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Registration Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued on conversion of the Working Capital Loan or Additional Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loan or Additional Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement signed in conjunction with the Initial Public Offering requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Company’s Class A common stock). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Underwriting Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,867,500 in the aggregate. The deferred fee will be waived by the underwriters in the event that the Company does not complete a Business Combination by January 28, 2023, subject to the terms of the underwriting agreement.</p> 3 0.35 10867500 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 8. STOCKHOLDERS’ DEFICIT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock </span>— The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The board of directors is able to, without stockholder approval, issue shares of preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the common stock and could have anti-takeover effects. At June 30, 2022 and December 31, 2021, there were no shares of preferred stock issued or outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class A Common Stock </span>— The Company is authorized to issue 400,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were no shares of Class A common stock issued and outstanding, excluding 31,050,000 shares of Class A common stock subject to possible redemption, which are presented as temporary equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class B Common Stock</span><b style="font-weight:bold;"> </b>— The Company is authorized to issue 40,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were 7,762,500 shares of Class B common stock issued and outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of Class B common stock have the right to elect all of the Company’s directors prior to a Business Combination. Holders of Class A common stock and Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders except as required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Class B common stock will automatically convert into Class A common stock at the time of the completion of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which Founder Shares will convert into Class A common stock will be adjusted (subject to waiver by holders of a majority of the Class B common stock) so that the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of the common stock issued and outstanding upon completion of the Initial Public Offering plus the number of shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination, excluding any shares of Class A common stock or equity-linked securities issued, or to be issued, to any seller in a Business Combination.</p> 1000000 0.0001 0 0 400000000 0.0001 1 0 0 31050000 40000000 0.0001 1 7762500 7762500 1 20 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 9.</b> <b style="font-weight:bold;">WARRANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span>— Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months after the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement governing the Warrants (the “Warrant Agreement”). The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However except as described below, the warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination by January 28, 2023 or during an Extension Period and the Company liquidates the funds held in the Trust Account, holders of the warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution form the Company’s assets held outside the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the completion of the Company’s initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of shares of the Company’s Class A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummate a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00” and “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration or a valid exemption from registration is available. No Public Warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their Public Warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement registering the issuance, under the Securities Act, of the Class A common stock issuable upon exercise of the Public Warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the Warrant Agreement. Notwithstanding the above, if the Class A common stock is, at the time of any exercise of a Public Warrant, not listed on a national securities exchange such that they do not satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their Public Warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds </i><i style="font-style:italic;">$18.00</i>. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in whole and not in part;</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at a price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.01</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per Public Warrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon not less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">’ prior written notice of redemption to each warrant holder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, and only if, the last reported sale price of shares of the Class A common stock for any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> trading days within a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$18.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant).</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds </i><i style="font-style:italic;">$10.00</i>. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="display:inline-block;width:0pt;"/><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in whole and not in part;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.10</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per warrant upon a minimum of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the “fair market value” of the Class A common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, and only if, the Reference Value equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$10.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share (as adjusted); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the Reference Value is less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$18.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when the Public Warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">The Private Placement Warrants are identical to the Public Warrants underlying the Units that were sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and are exercisable by such holders on the same basis as the Public Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Warrants are not considered to be indexed to the Company’s stock price. In accordance with ASC 815, the warrants were classified as a liability in the total amount of $11.6 million at January 28, 2021. In addition, the warrants must be valued every reporting period and adjusted to market value with the increase or decrease being adjusted through earnings. As of June 30, 2022 and December 31, 2021, the fair value of the warrant liability was $1,424,100 and $8,544,600, respectively.</p> P30D P12M P5Y 9.20 0.60 20 9.20 1.15 18.00 18.00 10.00 1.80 10.00 10.00 P15D P60D 18.00 0.01 P30D 20 30 18.00 10.00 0.10 P30D 10.00 18.00 P30D 11600000 1424100 8544600 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 10.</b> <b style="font-weight:bold;">FAIR VALUE MEASUREMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents fair value information at June 30, 2022 and December 31, 2021 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. The Company’s warrant liability is based on a valuation model utilizing management’s judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. The fair value of the Private Placement Warrants liability is classified within Level 3 of the fair value hierarchy. There was no transfer of fair value measurements between levels of the fair value hierarchy for the three and six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following tables set forth by level within the fair value hierarchy the Company’s assets and liabilities that were accounted for at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022 (unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and marketable securities held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,780,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 931,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 492,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and marketable securities held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,544,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,589,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,955,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Measurement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At June 30, 2022, the Company’s warrant liability was valued at $1,424,100. Under the guidance in Subtopic 815-40, the Public Warrants and the Private Placement Warrants do not meet the criteria for equity treatment. As such, the Public Warrants and the Private Placement Warrants must be recorded as a liability on the balance sheet at fair value. This valuation is subject to re-measurement at each balance sheet date. With each re-measurement, the valuations will be adjusted to fair value, with the change in fair value recognized in the Company’s condensed statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Warrants were initially valued using a Monte Carlo simulation model, with the observable assumptions as provided in the table below. Significant increases in the expected stock prices and expected liquidity would result in a significantly higher fair value measurement. Significant increases in either the probability or severity of default of the host instrument would result in a significantly lower fair value measurement. The measurement of the Public Warrants after the detachment of the Public Warrants from the Units is classified as Level 1 due to the use of an observable market quote in an active market. For periods subsequent to the detachment of the Public Warrants from the Units, the closing price of the Public Warrants was used as the fair value for the Public Warrants as of each relevant date. The Private Placement Warrants are valued using a Monte Carlo simulation model at each reporting period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The key inputs into the Monte Carlo simulation model formula utilized to value the Private Placement Warrants were as follows at June 30, 2022 and December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Input</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant to buy one share (unadjusted for the probability of dissolution)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant to buy one share (adjusted for the probability of dissolution)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:17.85pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022 (unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and marketable securities held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,780,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 931,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 492,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and marketable securities held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,544,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Public Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,589,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:56.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Private Placement Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,955,600</p></td></tr></table> 310780579 931500 492600 310544829 0 5589000 0 0 2955600 1424100 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Input</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant to buy one share (unadjusted for the probability of dissolution)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant to buy one share (adjusted for the probability of dissolution)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table> 9.81 9.75 11.50 11.50 2.97 1.34 6.31 9.10 5.51 6.00 0.60 0.54 0.09 0.54 0.00 0.00 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 11. INCOME TAX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the three and six months ended June 30, 2022, the Company did not record any income tax benefits for the net operating losses incurred due to the uncertainty of realizing a benefit from those items. Taxes generated on the interest income on amounts held in the Trust Account are offset by the net operating losses and valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. The Company considered the history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies, and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. As such, the Company recorded a full valuation allowance against net deferred tax assets as of June 30, 2022 and December 31, 2021.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 12. SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 119 207 1 false 38 0 false 7 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Balance Sheets Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Statements of Operations (unaudited) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (unaudited) Statements 4 false false R5.htm 00300 - Statement - Condensed Statements of Changes in Stockholders' Deficit (unaudited) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited Condensed Statements of Changes in Stockholders' Deficit (unaudited) Statements 5 false false R6.htm 00305 - Statement - Condensed Statements of Changes in Stockholders' Deficit (unaudited) (Parenthetical) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical Condensed Statements of Changes in Stockholders' Deficit (unaudited) (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - Condensed Statements of Cash Flows (unaudited) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (unaudited) Statements 7 false false R8.htm 10101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperations ORGANIZATION AND PLANS OF BUSINESS OPERATIONS Notes 8 false false R9.htm 10201 - Disclosure - REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatements REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS Notes 9 false false R10.htm 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 10401 - Disclosure - INITIAL PUBLIC OFFERING Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOffering INITIAL PUBLIC OFFERING Notes 11 false false R12.htm 10501 - Disclosure - PRIVATE PLACEMENT Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacement PRIVATE PLACEMENT Notes 12 false false R13.htm 10601 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 10701 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 10801 - Disclosure - STOCKHOLDERS' DEFICIT Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficit STOCKHOLDERS' DEFICIT Notes 15 false false R16.htm 10901 - Disclosure - WARRANTS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrants WARRANTS Notes 16 false false R17.htm 11001 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurements FAIR VALUE MEASUREMENTS Notes 17 false false R18.htm 11101 - Disclosure - INCOME TAX Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureIncomeTax INCOME TAX Notes 18 false false R19.htm 11201 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 19 false false R20.htm 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 30203 - Disclosure - REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsTables REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables) Tables http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatements 21 false false R22.htm 30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 31003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurements 23 false false R24.htm 40101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperations 24 false false R25.htm 40201 - Disclosure - REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Company's Condensed Statements of Cash Flows (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Company's Condensed Statements of Cash Flows (Details) Details 25 false false R26.htm 40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net income per common share (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net income per common share (Details) Details 27 false false R28.htm 40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption (Details) Details 28 false false R29.htm 40401 - Disclosure - INITIAL PUBLIC OFFERING (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails INITIAL PUBLIC OFFERING (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOffering 29 false false R30.htm 40501 - Disclosure - PRIVATE PLACEMENT (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails PRIVATE PLACEMENT (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacement 30 false false R31.htm 40601 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails RELATED PARTY TRANSACTIONS - Founder Shares (Details) Details 31 false false R32.htm 40602 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails RELATED PARTY TRANSACTIONS - Additional Information (Details) Details 32 false false R33.htm 40701 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsAndContingencies 33 false false R34.htm 40801 - Disclosure - STOCKHOLDERS' DEFICIT - Preferred Stock Shares (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitPreferredStockSharesDetails STOCKHOLDERS' DEFICIT - Preferred Stock Shares (Details) Details 34 false false R35.htm 40802 - Disclosure - STOCKHOLDERS' DEFICIT - Common Stock Shares (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails STOCKHOLDERS' DEFICIT - Common Stock Shares (Details) Details 35 false false R36.htm 40901 - Disclosure - WARRANTS (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails WARRANTS (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrants 36 false false R37.htm 41001 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables 37 false false R38.htm 41002 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value Measurements Inputs (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails FAIR VALUE MEASUREMENTS - Fair Value Measurements Inputs (Details) Details 38 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 50 fact(s) appearing in ix:hidden were eligible for transformation: ssaau:NumberOfWarrantsIssuedPerUnit, ssaau:TemporaryEquityGrossProceedsFromInitialPublicOffering, ssaau:TemporaryEquityIssuanceCosts, ssaau:TemporaryEquityProceedsAllocatedToPublicWarrants, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:TemporaryEquityAccretionToRedemptionValue, us-gaap:TemporaryEquityCarryingAmountAttributableToParent, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - ssaau-20220630x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies - ssaau-20220630x10q.htm 9 ssaau-20220630x10q.htm ssaau-20220630.xsd ssaau-20220630_cal.xml ssaau-20220630_def.xml ssaau-20220630_lab.xml ssaau-20220630_pre.xml ssaau-20220630xex31d1.htm ssaau-20220630xex31d2.htm ssaau-20220630xex32d1.htm ssaau-20220630xex32d2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ssaau-20220630x10q.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 119, "dts": { "calculationLink": { "local": [ "ssaau-20220630_cal.xml" ] }, "definitionLink": { "local": [ "ssaau-20220630_def.xml" ] }, "inline": { "local": [ "ssaau-20220630x10q.htm" ] }, "labelLink": { "local": [ "ssaau-20220630_lab.xml" ] }, "presentationLink": { "local": [ "ssaau-20220630_pre.xml" ] }, "schema": { "local": [ "ssaau-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 321, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 48, "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630": 4, "http://xbrl.sec.gov/dei/2022": 5, "total": 57 }, "keyCustom": 74, "keyStandard": 133, "memberCustom": 19, "memberStandard": 19, "nsprefix": "ssaau", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - INITIAL PUBLIC OFFERING", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOffering", "shortName": "INITIAL PUBLIC OFFERING", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - PRIVATE PLACEMENT", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacement", "shortName": "PRIVATE PLACEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - STOCKHOLDERS' DEFICIT", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficit", "shortName": "STOCKHOLDERS' DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:WarrantLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - WARRANTS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrants", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:WarrantLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - INCOME TAX", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureIncomeTax", "shortName": "INCOME TAX", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Balance Sheets", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsTables", "shortName": "REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_1_28_2021_ezzgxTY230i_Fk9XNxTn-A", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_j-hsJAonBUiw0CMOWXMMzw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "shortName": "ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_1_28_2021_ezzgxTY230i_Fk9XNxTn-A", "decimals": "0", "lang": null, "name": "ssaau:TransactionCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_DWLKJ0dJzUu5MUliEJV--A", "decimals": "0", "first": true, "lang": null, "name": "ssaau:TransactionCostsAllocableToWarrants", "reportCount": 1, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Company's Condensed Statements of Cash Flows (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails", "shortName": "REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Company's Condensed Statements of Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_Ir6FXNhr1UiczLTOO_IP3w", "decimals": "0", "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "ssaau:OfferingCostsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": "-5", "first": true, "lang": null, "name": "ssaau:OfferingCostOfStockIssuanceInInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ssaau:OfferingCostsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": "-5", "first": true, "lang": null, "name": "ssaau:OfferingCostOfStockIssuanceInInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_DkKqgoaSYUKGKd7KS39Egg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net income per common share (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net income per common share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_ssaau_CommonClassaSubjectToRedemptionMember_UoDhms4Q9EycrC88mNh5cQ", "decimals": "0", "lang": null, "name": "us-gaap:TemporaryEquityNetIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_ssaau_CommonClassaSubjectToRedemptionMember_vLpICxcYc0yJh6uiCZ0bRg", "decimals": "0", "first": true, "lang": null, "name": "ssaau:TemporaryEquityGrossProceedsFromInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A common stock subject to possible redemption (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_ssaau_CommonClassaSubjectToRedemptionMember_vLpICxcYc0yJh6uiCZ0bRg", "decimals": "0", "first": true, "lang": null, "name": "ssaau:TemporaryEquityGrossProceedsFromInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_1_28_2021_ezzgxTY230i_Fk9XNxTn-A", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_j-hsJAonBUiw0CMOWXMMzw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - INITIAL PUBLIC OFFERING (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "shortName": "INITIAL PUBLIC OFFERING (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ssaau:InitialPublicOfferingTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_28_2021_To_1_28_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oyMFswytrkC-4xDSxruXjQ", "decimals": "INF", "lang": null, "name": "ssaau:NumberOfSharesIssuedPerUnit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_kVs4yLuUdECBBnC_CQBJiA", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_j-hsJAonBUiw0CMOWXMMzw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Balance Sheets (Parenthetical)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "p", "ssaau:WarrantInstrumentsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_kVs4yLuUdECBBnC_CQBJiA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - PRIVATE PLACEMENT (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "shortName": "PRIVATE PLACEMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ssaau:PrivatePlacementTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_1_28_2021_us-gaap_ClassOfWarrantOrRightAxis_ssaau_PrivatePlacementWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GC94Fcz_ckiZ7jo7rH6wWg", "decimals": "2", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_j-hsJAonBUiw0CMOWXMMzw", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_10_29_2020_To_10_29_2020_us-gaap_RelatedPartyTransactionAxis_ssaau_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ssaau_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_OdmCA-yNw0q8aTfjHn1HVQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_kVs4yLuUdECBBnC_CQBJiA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "shortName": "RELATED PARTY TRANSACTIONS - Founder Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_10_29_2020_To_10_29_2020_us-gaap_RelatedPartyTransactionAxis_ssaau_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ssaau_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_OdmCA-yNw0q8aTfjHn1HVQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_kVs4yLuUdECBBnC_CQBJiA", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "ssaau:WorkingCapitalLoanPayablePolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_hdnPw_eAzE-JEfbDqNepAA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesClassifiedCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "RELATED PARTY TRANSACTIONS - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_RelatedPartyTransactionAxis_ssaau_RelatedPartyLoansMember_c65kf9355kC--mtzwVNJAw", "decimals": "0", "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "0", "first": true, "lang": null, "name": "ssaau:FounderSharesAndWarrantsDemands", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_4N9G56FYq0eat7CnZCk4lw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "0", "first": true, "lang": null, "name": "ssaau:FounderSharesAndWarrantsDemands", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_4N9G56FYq0eat7CnZCk4lw", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_kVs4yLuUdECBBnC_CQBJiA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - STOCKHOLDERS' DEFICIT - Preferred Stock Shares (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitPreferredStockSharesDetails", "shortName": "STOCKHOLDERS' DEFICIT - Preferred Stock Shares (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "0", "first": true, "lang": null, "name": "ssaau:CommonStockClassBConversionToClass", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_xRrUciXBqUelQg1Bd7hLfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - STOCKHOLDERS' DEFICIT - Common Stock Shares (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "shortName": "STOCKHOLDERS' DEFICIT - Common Stock Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "0", "first": true, "lang": null, "name": "ssaau:CommonStockClassBConversionToClass", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_xRrUciXBqUelQg1Bd7hLfg", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares", "reportCount": 1, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - WARRANTS (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "shortName": "WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ssaau:WarrantLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_ssaau_PublicWarrantsMember_Y0P7qeLdLUiR_Xt3gSejfg", "decimals": null, "lang": "en-US", "name": "ssaau:WarrantsAndRightsOutstandingExercisablePeriodAfterBusinessCombination", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_HHxQL83W4k2U_67zv1FEfA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1Tp4Hs7SvU6jNTKn0kYMVA", "decimals": "0", "lang": null, "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_ssaau_PrivatePlacementWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_cCKSAmQC90OqozYuxMGcvQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_xRrUciXBqUelQg1Bd7hLfg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value Measurements Inputs (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Fair Value Measurements Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_ssaau_PrivatePlacementWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_cCKSAmQC90OqozYuxMGcvQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_xRrUciXBqUelQg1Bd7hLfg", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_DkKqgoaSYUKGKd7KS39Egg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Statements of Operations (unaudited)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited", "shortName": "Condensed Statements of Operations (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_DkKqgoaSYUKGKd7KS39Egg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9rUPT5zPXUqckkBbJOvDCw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Statements of Changes in Stockholders' Deficit (unaudited)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "shortName": "Condensed Statements of Changes in Stockholders' Deficit (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2UukhYOo0UqZNxs9E_f41Q", "decimals": "0", "lang": null, "name": "ssaau:AdjustmentsToAdditionalPaidInCapitalProceedsReceivedInExcessOfFairValueOfPrivateWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_ssaau_CommonClassaSubjectToRedemptionMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6cZvYctcskadAnAaEhEcmg", "decimals": "0", "first": true, "lang": null, "name": "ssaau:TemporaryEquitySharesNewIssues", "reportCount": 1, "unitRef": "Unit_Standard_shares_kVs4yLuUdECBBnC_CQBJiA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - Condensed Statements of Changes in Stockholders' Deficit (unaudited) (Parenthetical)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical", "shortName": "Condensed Statements of Changes in Stockholders' Deficit (unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Statements of Cash Flows (unaudited)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Statements of Cash Flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_oDMh6ItyQEaXX4EyZP3UaA", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperations", "shortName": "ORGANIZATION AND PLANS OF BUSINESS OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatements", "shortName": "REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_nQKfGwi5YEWtjDz2cuEr7A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 38, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r66", "r67", "r68", "r69", "r70", "r71", "r72", "r73", "r74", "r76", "r77", "r78", "r79", "r80", "r81", "r95", "r122", "r123", "r206", "r222", "r223", "r224", "r225", "r246", "r247", "r248", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r66", "r67", "r68", "r69", "r70", "r71", "r72", "r73", "r74", "r76", "r77", "r78", "r79", "r80", "r81", "r95", "r122", "r123", "r206", "r222", "r223", "r224", "r225", "r246", "r247", "r248", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r1", "r66", "r68", "r69", "r70", "r71", "r72", "r73", "r74", "r76", "r77", "r79", "r80", "r95", "r122", "r123", "r206", "r222", "r223", "r224", "r225", "r246", "r247", "r248", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "label": "As Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r75", "r81", "r129", "r189" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r75", "r81", "r129", "r189", "r261" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "ssaau_AccruedOfferingCost": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of offering costs accrued but not yet paid as of the period date.", "label": "Accrued Offering Cost", "terseLabel": "Accrued offering costs" } } }, "localname": "AccruedOfferingCost", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ssaau_AdjustmentsToAdditionalPaidInCapitalProceedsReceivedInExcessOfFairValueOfPrivateWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in proceeds received in excess of fair value of private warrants of common and preferred stock issued to employee benefit trust but unearned.", "label": "Adjustments to Additional Paid in Capital, Proceeds Received In Excess Of Fair Value Of Private Warrants", "terseLabel": "Proceeds received in excess of fair value of public warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalProceedsReceivedInExcessOfFairValueOfPrivateWarrants", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_AdministrativeServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to administrative services agreement.", "label": "Administrative Services Agreement" } } }, "localname": "AdministrativeServicesAgreementMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ssaau_AggregateNumberOfSharesOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares owned by the founders after the impact of the stock dividend.", "label": "Aggregate Number Of Shares Owned", "terseLabel": "Aggregate number of shares owned" } } }, "localname": "AggregateNumberOfSharesOwned", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "ssaau_AggregateProceedsHeldInTrustAccount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of aggregate proceeds held in the Trust Account.", "label": "Aggregate Proceeds Held In Trust Account", "terseLabel": "Aggregate proceeds held in trust account" } } }, "localname": "AggregateProceedsHeldInTrustAccount", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_AmountAccruedOrPaidRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount accrued or paid to related party.", "label": "Amount Accrued Or Paid, Related Party", "terseLabel": "Amount accrued or paid" } } }, "localname": "AmountAccruedOrPaidRelatedParty", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_AmountHeldInTrustAccountFromPrivatePlacementWarrantsIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount held in the trust account from private placement warrants issuance proceeds.", "label": "Amount Held In The Trust Account From Private Placement Warrants Issuance", "terseLabel": "Amount held in the trust account from private placement warrants issuance proceeds" } } }, "localname": "AmountHeldInTrustAccountFromPrivatePlacementWarrantsIssuance", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_AssetsHeldInTrustAccountPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of accounting policy for assets held in trust.", "label": "Assets Held In Trust Account, Policy [Policy Text Block]", "terseLabel": "Marketable Securities Held in Trust Account" } } }, "localname": "AssetsHeldInTrustAccountPolicyPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of adjustment of exercise price of warrants based on market value and newly issued price.", "label": "Class of Warrant or Right, Adjustment of Exercise Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Share Price", "terseLabel": "Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)" } } }, "localname": "ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedSharePrice", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "percentItemType" }, "ssaau_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of adjustment of redemption price of stock based on market value and newly issued price.", "label": "Class of Warrant or Right, Adjustment of Redemption Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Price 1", "terseLabel": "Adjustment of redemption price of stock based on market value and newly issued price (as a percent)" } } }, "localname": "ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "percentItemType" }, "ssaau_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class Of Warrant Or Right, Minimum Threshold Written Notice Period For Redemption Of Warrants", "terseLabel": "Minimum threshold written notice period for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrants", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_ClassOfWarrantOrRightPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Price of Warrants or Rights", "terseLabel": "Price of warrant", "verboseLabel": "Price of warrants" } } }, "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "ssaau_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained to trigger the redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Right, Stock Price Trigger", "terseLabel": "Stock price trigger for redemption of public warrants (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ssaau_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "integerItemType" }, "ssaau_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days", "terseLabel": "Threshold trading days for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "integerItemType" }, "ssaau_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights", "terseLabel": "Redemption price per warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ssaau_CommonClassaNotSubjectToRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation that is not subject to redemption.", "label": "Class A Common Stock Not Subject to Redemption" } } }, "localname": "CommonClassaNotSubjectToRedemptionMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "ssaau_CommonClassaSubjectToRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation that is subject to redemption.", "label": "Class A Common Stock Subject to Redemption" } } }, "localname": "CommonClassaSubjectToRedemptionMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "ssaau_CommonStockClassBConversionToClass": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of Common Stock Class B into Common Stock Class A.", "label": "Common Stock Class B Conversion to Class A", "terseLabel": "Class B common stock conversion ratio to Class B" } } }, "localname": "CommonStockClassBConversionToClass", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails" ], "xbrltype": "pureItemType" }, "ssaau_CommonStockNumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of votes that each common share is entitled.", "label": "Common Stock, Number Of Votes Per Share", "terseLabel": "Common shares, votes per share" } } }, "localname": "CommonStockNumberOfVotesPerShare", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails" ], "xbrltype": "integerItemType" }, "ssaau_ConvertibleStockConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The ratio to be applied to the stock in a conversion of convertible stock.", "label": "Convertible Stock Conversion Ratio", "terseLabel": "Ratio to be applied to the stock in the conversion" } } }, "localname": "ConvertibleStockConversionRatio", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails" ], "xbrltype": "pureItemType" }, "ssaau_DeferredFeePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the deferred fee per unit.", "label": "Deferred Fee Per Unit", "terseLabel": "Deferred fee per unit" } } }, "localname": "DeferredFeePerUnit", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "perShareItemType" }, "ssaau_DeferredOfferingCostsIncludedInAccruedOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred offering costs included in accrued offering cost.", "label": "Deferred Offering Costs Included In Accrued Offering Cost", "terseLabel": "Deferred offering costs included in accrued offering costs" } } }, "localname": "DeferredOfferingCostsIncludedInAccruedOfferingCost", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_DeferredOfferingCostsNoncurrent": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails": { "order": 2.0, "parentTag": "ssaau_TransactionCosts", "weight": 1.0 }, "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.", "label": "Deferred Offering Costs Noncurrent", "terseLabel": "Deferred underwriting fee payable" } } }, "localname": "DeferredOfferingCostsNoncurrent", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ssaau_DenominatorForCalculationOfEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Denominator For Calculation Of Earnings Per Share [Abstract]", "terseLabel": "Denominator: Weighted average Class of common stock" } } }, "localname": "DenominatorForCalculationOfEarningsPerShareAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "ssaau_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy on Emerging Growth Company.", "label": "Emerging Growth Company [Policy Text Block]", "terseLabel": "Emerging Growth Company" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_FounderSharesAndWarrantsDemands": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of demands the Founder Shares, Private Placement Warrants and any warrants that may be issued on conversion of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) are entitled to.", "label": "Founder Shares and Warrants Demands", "terseLabel": "Number of demands securities are entitled to" } } }, "localname": "FounderSharesAndWarrantsDemands", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "ssaau_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to founder shares.", "label": "Founder Shares" } } }, "localname": "FounderSharesMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "ssaau_IncreaseDecreaseInAccruedOfferingCosts": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount representing the increase decrease in accrued offering costs.", "label": "Increase Decrease In Accrued Offering Costs", "terseLabel": "Accrued offering costs" } } }, "localname": "IncreaseDecreaseInAccruedOfferingCosts", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_InitialClassificationOfClassCommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Initial classification of Class A common stock subject to possible redemption", "label": "Initial Classification Of Class A Common Stock Subject To Possible Redemption", "terseLabel": "Initial classification of Class A common stock subject to possible redemption" } } }, "localname": "InitialClassificationOfClassCommonStockSubjectToPossibleRedemption", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_InitialFairValueOfWarrantLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The initial fair value classification of warrant liabilities disclosed in the supplemental non-cash cash flow activities.", "label": "Initial Fair Value Of Warrant Liabilities", "verboseLabel": "Initial fair value of warrant liability" } } }, "localname": "InitialFairValueOfWarrantLiabilities", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "INITIAL PUBLIC OFFERING" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "xbrltype": "stringItemType" }, "ssaau_InitialPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on information about initial public offering.", "label": "Initial Public Offering [Text Block]", "terseLabel": "INITIAL PUBLIC OFFERING" } } }, "localname": "InitialPublicOfferingTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "ssaau_MaturityDaysOfFundsInTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Maturity days of funds in the Trust Account.", "label": "Maturity days of funds in the Trust Account", "terseLabel": "Maturity days of funds in the trust account" } } }, "localname": "MaturityDaysOfFundsInTrustAccount", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "durationItemType" }, "ssaau_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum borrowing capacity of related party promissory note.", "label": "Maximum Borrowing Capacity of Related Party Promissory Note", "terseLabel": "Maximum borrowing capacity of related party promissory note" } } }, "localname": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_MaximumInterestToPayDissolutionExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum interest to pay dissolution expenses.", "label": "Maximum Interest To Pay Dissolution Expenses", "terseLabel": "Maximum interest to pay dissolution expenses" } } }, "localname": "MaximumInterestToPayDissolutionExpenses", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.", "label": "Maximum Period After Business Combination In Which To File Registration Statement", "terseLabel": "Maximum period after business combination in which to file registration statement" } } }, "localname": "MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_MaximumThresholdPeriodForRegistrationStatementToBecomeEffectiveAfterBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum threshold period for registration statement to become effective after business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Threshold Period For Registration Statement To Become Effective After Business Combination", "terseLabel": "Maximum threshold period for registration statement to become effective after business combination" } } }, "localname": "MaximumThresholdPeriodForRegistrationStatementToBecomeEffectiveAfterBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_MinimumNetTangibleAssetsUponConsummationOfBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The threshold net tangible assets which the reporting entity must maintain in order to proceed with a business combination utilizing the proceeds of the offering.", "label": "Minimum Net Tangible Assets Upon Consummation Of Business Combination", "terseLabel": "Minimum net tangible assets upon consummation of business combination" } } }, "localname": "MinimumNetTangibleAssetsUponConsummationOfBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_NetProceedsFromInitialPublicOffering": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public, net of underwriting discounts paid.", "label": "Net Proceeds From Initial Public Offering", "terseLabel": "Proceeds from sale of Units, net of underwriting discounts paid", "verboseLabel": "Proceeds from sale of Units, net of underwriting discounts paid" } } }, "localname": "NetProceedsFromInitialPublicOffering", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_NonRedeemableClassBCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Non Redeemable Class B Common Stock.", "label": "Non redeemable Class B common stock" } } }, "localname": "NonRedeemableClassBCommonStockMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "ssaau_NumberOfDaysToRedeemSharesIfBusinessCombinationIsNotCompletedBySpecifiedDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of days to redeem shares if business combination is not completed by specified date.", "label": "Number Of Days To Redeem Shares If Business Combination Is Not Completed By Specified Date", "terseLabel": "Number of days to redeem shares if business combination is not completed by specified date" } } }, "localname": "NumberOfDaysToRedeemSharesIfBusinessCombinationIsNotCompletedBySpecifiedDate", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "durationItemType" }, "ssaau_NumberOfSharesIssuedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares in a unit.", "label": "Number of Shares Issued Per Unit", "terseLabel": "Number of shares in a unit" } } }, "localname": "NumberOfSharesIssuedPerUnit", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "ssaau_NumberOfWarrantsIssuedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants in a unit.", "label": "Number of Warrants Issued Per Unit", "terseLabel": "Number of warrants in a unit" } } }, "localname": "NumberOfWarrantsIssuedPerUnit", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "ssaau_NumeratorForCalculationOfEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Numerator For Calculation Of Earnings Per Share [Abstract]", "terseLabel": "Numerator: Income (loss) attributable to Class A Common Stock subject to possible redemption" } } }, "localname": "NumeratorForCalculationOfEarningsPerShareAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "ssaau_OfferingCostOfStockIssuanceInInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of stock offering cost in initial public offering.", "label": "Offering Cost Of Stock Issuance In Initial Public Offering", "terseLabel": "Offering costs charged to shareholders' equity" } } }, "localname": "OfferingCostOfStockIssuanceInInitialPublicOffering", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_OfferingCostsAllocatedToWarrantLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of offering costs allocated to warrant liability.", "label": "Offering Costs Allocated To Warrant Liability", "terseLabel": "Offering costs related to warrant liabilities" } } }, "localname": "OfferingCostsAllocatedToWarrantLiability", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_OfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy on offering costs.", "label": "Offering Costs Policy [Text Block]", "terseLabel": "Offering Costs" } } }, "localname": "OfferingCostsPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_PaymentsForInvestmentOfCashInTrustAccount": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for investment of cash in trust account.", "label": "Payments for investment of cash in Trust Account", "negatedLabel": "Investment of cash in Trust Account" } } }, "localname": "PaymentsForInvestmentOfCashInTrustAccount", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of shares which the reporting entity is obligated to redeem if a business combination is not consummated using the offering proceeds within a specified period.", "label": "Percentage Obligation To Redeem Public Shares If Entity Does Not Complete A Business Combination", "terseLabel": "Obligation to redeem public shares if entity does not complete a business combination (as a percent)" } } }, "localname": "PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "ssaau_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.", "label": "Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant", "terseLabel": "Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant" } } }, "localname": "PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "percentItemType" }, "ssaau_PrivatePlacementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "PRIVATE PLACEMENT" } } }, "localname": "PrivatePlacementAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "xbrltype": "stringItemType" }, "ssaau_PrivatePlacementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on information about private placement.", "label": "Private Placement [Text Block]", "terseLabel": "PRIVATE PLACEMENT" } } }, "localname": "PrivatePlacementTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacement" ], "xbrltype": "textBlockItemType" }, "ssaau_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.", "label": "Private Placement Warrants" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "ssaau_ProceedsFromWorkingCapitalLoan": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from working capital loan.", "label": "Proceeds From Working Capital Loan", "terseLabel": "Proceeds from working capital loan" } } }, "localname": "ProceedsFromWorkingCapitalLoan", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_PromissoryNoteWithRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for promissory note with related party.", "label": "Promissory Note with Related Party" } } }, "localname": "PromissoryNoteWithRelatedPartyMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ssaau_PublicAndPrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Public and Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.", "label": "Public And Private Placement Warrants" } } }, "localname": "PublicAndPrivatePlacementWarrantsMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "ssaau_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.", "label": "Public Warrants" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "ssaau_RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the redemption of shares calculated based on number of business days prior to consummation of business combination.", "label": "Redemption of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination", "terseLabel": "Redemption of shares calculated based on business days prior to consummation of business combination (in days)" } } }, "localname": "RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "integerItemType" }, "ssaau_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $10.00.", "label": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00" } } }, "localname": "RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "ssaau_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $18.00.", "label": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00" } } }, "localname": "RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "ssaau_RelatedPartyLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for related party loans.", "label": "Related Party Loans" } } }, "localname": "RelatedPartyLoansMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ssaau_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The contractual monthly amount to be paid for support services.", "label": "Related Party Transaction, Expenses from Transactions with Related Party Per Month", "terseLabel": "Expenses per month" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_RemeasurementOfCommonStockSubjectToRedemptionCashFlow": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the remeasurement of common stock subject to possible redemption, as supplemental disclosure in the cash flow statement.", "label": "Remeasurement Of Common Stock Subject To Redemption, Cash Flow", "terseLabel": "Remeasurement of Class A common stock subject to possible redemption" } } }, "localname": "RemeasurementOfCommonStockSubjectToRedemptionCashFlow", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after completion of a business combination during which the shares or warrant may not be transferred.", "label": "Restrictions On Transfer Period Of Time After Business Combination Completion", "terseLabel": "Restrictions on transfer period of time after business combination completion" } } }, "localname": "RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_SaleOfStockOtherOfferingCosts": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails": { "order": 3.0, "parentTag": "ssaau_TransactionCosts", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of other offering costs incurred.", "label": "Sale of Stock, Other Offering Costs", "terseLabel": "Other offering costs" } } }, "localname": "SaleOfStockOtherOfferingCosts", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_SaleOfStockUnderwritingFees": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails": { "order": 1.0, "parentTag": "ssaau_TransactionCosts", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of offering fees incurred and paid for underwriters.", "label": "Sale of Stock, Underwriting fees", "terseLabel": "Underwriting fees" } } }, "localname": "SaleOfStockUnderwritingFees", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for sponsor.", "label": "Sponsor" } } }, "localname": "SponsorMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "ssaau_StockholdersEquityRemeasurementOfTemporaryEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The effect on stockholders' equity from re-measurement of temporary equity.", "label": "Stockholders' Equity, Remeasurement of Temporary Equity", "negatedLabel": "Remeasurement of Class A common stock subject to possible redemption" } } }, "localname": "StockholdersEquityRemeasurementOfTemporaryEquity", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_TemporaryEquityGrossProceedsFromInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of gross proceeds from initial public offering relating to temporary equity.", "label": "Temporary Equity Gross Proceeds From Initial Public Offering", "terseLabel": "Gross proceeds from initial public offering" } } }, "localname": "TemporaryEquityGrossProceedsFromInitialPublicOffering", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_TemporaryEquityIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of issuance costs related to temporary equity.", "label": "Temporary Equity Issuance Costs", "terseLabel": "Offering costs allocated to Class A common stock subject to possible redemption" } } }, "localname": "TemporaryEquityIssuanceCosts", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_TemporaryEquityPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of accounting policy for temporary equity.", "label": "Temporary Equity, Policy [Policy Text Block]", "terseLabel": "Class A Common Stock Subject to Possible Redemption" } } }, "localname": "TemporaryEquityPolicyPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_TemporaryEquityProceedsAllocatedToPublicWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of proceeds allocated to public warrants related to temporary equity.", "label": "Temporary Equity Proceeds Allocated To Public Warrants", "terseLabel": "Proceeds allocated to public warrants" } } }, "localname": "TemporaryEquityProceedsAllocatedToPublicWarrants", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_TemporaryEquityRemeasurementOfValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in temporary equity from remeasurement of value.", "label": "Temporary Equity, Remeasurement Of Value", "terseLabel": "Remeasurement of Class A common stock subject to possible redemption" } } }, "localname": "TemporaryEquityRemeasurementOfValue", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_TemporaryEquitySharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new temporary stock issued during the period.", "label": "Temporary Equity, Shares, New Issues", "terseLabel": "Issuance of 31,050,000 Units (in shares)", "verboseLabel": "Issuance of units" } } }, "localname": "TemporaryEquitySharesNewIssues", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "ssaau_ThresholdIssuePriceForCapitalRaisingPurposesInConnectionWithClosingOfBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to threshold issue price for capital raising purposes in connection with the closure of a business combination.", "label": "Threshold Issue Price for Capital Raising Purposes in Connection with the Closing of a Business Combination", "terseLabel": "Threshold issue price per share" } } }, "localname": "ThresholdIssuePriceForCapitalRaisingPurposesInConnectionWithClosingOfBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ssaau_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the threshold minimum aggregate fair market value as a percentage of the net assets held in the Trust Account.", "label": "Threshold Minimum Aggregate Fair Market Value As Percentage Of Assets Held In Trust Account", "terseLabel": "Threshold minimum aggregate fair market value as percentage of assets held in trust account" } } }, "localname": "ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "ssaau_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.", "label": "Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences", "terseLabel": "Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences" } } }, "localname": "ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "durationItemType" }, "ssaau_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.", "label": "Trading Period After Business Combination Used To Measure Dilution of Warrant", "terseLabel": "Trading period after business combination used to measure dilution of warrant" } } }, "localname": "TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "integerItemType" }, "ssaau_TransactionCosts": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of transaction costs incurred.", "label": "Transaction Costs", "totalLabel": "Transaction costs" } } }, "localname": "TransactionCosts", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_TransactionCostsAllocableToWarrants": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction costs allocable to warrants.", "label": "Transaction Costs Allocable To Warrants", "terseLabel": "Warrant issuance costs" } } }, "localname": "TransactionCostsAllocableToWarrants", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ssaau_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger", "terseLabel": "Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "perShareItemType" }, "ssaau_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "integerItemType" }, "ssaau_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days", "terseLabel": "Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "integerItemType" }, "ssaau_UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Unit each consisting of one class common stock .", "label": "Unit Each Consisting Of One Class Common Stock And One Third of one Redeemable Warrant" } } }, "localname": "UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ssaau_UnitsIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new units issued during the period.", "label": "Units Issued During Period, Shares, New Issues", "verboseLabel": "Number of units sold" } } }, "localname": "UnitsIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "ssaau_WarrantInstrumentsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for Warrant Instruments.", "label": "Warrant Instruments, Policy [Policy Text Block]", "verboseLabel": "Warrants Exercisable for Class A Common Stock" } } }, "localname": "WarrantInstrumentsPolicyPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_WarrantLiabilitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Warrant Liabilities Disclosure [Text Block]", "terseLabel": "WARRANTS" } } }, "localname": "WarrantLiabilitiesDisclosureTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrants" ], "xbrltype": "textBlockItemType" }, "ssaau_WarrantToBuyOneShareAdjustedForProbabilityOfDissolutionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MeasurementInputWarrantToBuyOneShareAdjustedForProbabilityOfDissolution", "label": "Warrant to buy one share (adjusted for the probability of dissolution)" } } }, "localname": "WarrantToBuyOneShareAdjustedForProbabilityOfDissolutionMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "ssaau_WarrantToBuyOneShareUnadjustedForProbabilityOfDissolutionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MeasurementInputWarrantToBuyOneShareUnadjustedForProbabilityOfDissolution", "label": "Warrant to buy one share (unadjusted for the probability of dissolution)" } } }, "localname": "WarrantToBuyOneShareUnadjustedForProbabilityOfDissolutionMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "ssaau_WarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "WARRANTS" } } }, "localname": "WarrantsAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "xbrltype": "stringItemType" }, "ssaau_WarrantsAndRightsOutstandingExercisablePeriodAfterBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The warrants exercisable term after the completion of a business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Outstanding, Exercisable Period After Business Combination", "terseLabel": "Public Warrants exercisable term after the completion of a business combination" } } }, "localname": "WarrantsAndRightsOutstandingExercisablePeriodAfterBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_WarrantsAndRightsOutstandingExercisablePeriodFromClosingOfInitialPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The warrants exercisable term from the closing of the initial public offering, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Outstanding, Exercisable Period From Closing Of Initial Public Offering", "terseLabel": "Public Warrants exercisable term from the closing of the initial public offering" } } }, "localname": "WarrantsAndRightsOutstandingExercisablePeriodFromClosingOfInitialPublicOffering", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price.", "label": "Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50" } } }, "localname": "WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ssaau_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of working capital deficit.", "label": "Working Capital Deficit", "terseLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_WorkingCapitalLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to working capital loan.", "label": "Working Capital Loan" } } }, "localname": "WorkingCapitalLoanMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ssaau_WorkingCapitalLoanPayablePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for working capital loan payable.", "label": "Working Capital Loan Payable, Policy [Policy Text Block]", "terseLabel": "Working Capital Loan Payable" } } }, "localname": "WorkingCapitalLoanPayablePolicyPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_WorkingCapitalLoansWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Working capital loans warrant.", "label": "Working capital loans warrant" } } }, "localname": "WorkingCapitalLoansWarrantMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20220630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r28", "r64", "r253", "r254" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Related party payables" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20", "r259" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r66", "r67", "r68", "r191", "r192", "r193", "r223" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash used in operating activities:", "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Shares excluded from calculation of diluted income per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r13", "r62", "r111", "r113", "r117", "r120", "r131", "r132", "r133", "r135", "r136", "r137", "r138", "r139", "r140", "r142", "r143", "r213", "r217", "r236", "r257", "r259", "r279", "r287" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r26", "r62", "r120", "r131", "r132", "r133", "r135", "r136", "r137", "r138", "r139", "r140", "r142", "r143", "r213", "r217", "r236", "r257", "r259" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Cash and marketable securities held in Trust Account", "verboseLabel": "Marketable securities held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r62", "r120", "r131", "r132", "r133", "r135", "r136", "r137", "r138", "r139", "r140", "r142", "r143", "r213", "r217", "r236", "r257" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total Noncurrent Assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Noncurrent assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [TEXT BLOCK]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r11", "r56" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash held outside the Trust Account", "terseLabel": "Cash", "verboseLabel": "Cash held outside the trust account" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r51", "r56", "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash - End of period", "periodStartLabel": "Cash - Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r51", "r237" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Change in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Federal depository insurance coverage" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:", "verboseLabel": "Non-Cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r17", "r18", "r19", "r60", "r62", "r85", "r86", "r87", "r90", "r92", "r98", "r99", "r100", "r120", "r131", "r136", "r137", "r138", "r142", "r143", "r154", "r155", "r159", "r163", "r170", "r236", "r310" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r178", "r190" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants", "verboseLabel": "Exercise price of warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares issuable per warrant", "verboseLabel": "Number of shares per warrant" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Sale of private placement warrants (in shares)", "verboseLabel": "Number of warrants to purchase shares issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r178", "r190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r32", "r282", "r291" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r126", "r127", "r128", "r130", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Class A Common Stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Class B Common Stock" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common Stock Dividends, Shares", "terseLabel": "Share dividend" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r66", "r67", "r223" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common shares, par value, (per share)", "verboseLabel": "Common shares, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, shares authorized", "verboseLabel": "Common shares, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, shares issued", "verboseLabel": "Common shares, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r170" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares, shares outstanding", "verboseLabel": "Common shares, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19", "r259" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r104", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r44" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r176" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Debt Instrument, Convertible, Beneficial Conversion Feature", "terseLabel": "Proceeds" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r144", "r244", "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Debt Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability, Measurement Input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r28", "r64", "r134", "r136", "r137", "r141", "r142", "r143", "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Related party payables" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r42", "r71", "r72", "r74", "r75", "r76", "r82", "r85", "r90", "r91", "r92", "r95", "r96", "r224", "r225", "r284", "r293" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per share, Basic", "verboseLabel": "Basic net income (loss) per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r42", "r71", "r72", "r74", "r75", "r76", "r85", "r90", "r91", "r92", "r95", "r96", "r224", "r225", "r284", "r293" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per share, Diluted", "verboseLabel": "Diluted net income (loss) per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r38", "r39", "r40", "r66", "r67", "r68", "r70", "r77", "r80", "r97", "r121", "r170", "r177", "r191", "r192", "r193", "r205", "r206", "r223", "r238", "r239", "r240", "r241", "r242", "r243", "r248", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting error correction.", "label": "Accounting Changes and Error Corrections [Text Block]", "terseLabel": "REVISION OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS" } } }, "localname": "ErrorCorrectionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r54", "r148" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liability", "verboseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r226", "r227", "r232" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of quantitative information regarding fair value measurements inputs" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Company's assets that are measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r145", "r146", "r147", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r227", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r226", "r227", "r229", "r230", "r233" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r145", "r180", "r181", "r186", "r188", "r227", "r263" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r145", "r146", "r147", "r180", "r181", "r186", "r188", "r227", "r264" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r145", "r146", "r147", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r227", "r265" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r145", "r146", "r147", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r188", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r231", "r233" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Operations (unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAX" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r63", "r197", "r200", "r203", "r207", "r208", "r209", "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAX" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureIncomeTax" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r37", "r195", "r196", "r200", "r201", "r202", "r204" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r53" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties, Current", "terseLabel": "Related party payable" } } }, "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r53" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses, net of amortization" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r62", "r114", "r120", "r131", "r132", "r133", "r136", "r137", "r138", "r139", "r140", "r142", "r143", "r214", "r217", "r218", "r236", "r257", "r258" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r62", "r120", "r236", "r259", "r281", "r290" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r31", "r62", "r120", "r131", "r132", "r133", "r136", "r137", "r138", "r139", "r140", "r142", "r143", "r214", "r217", "r218", "r236", "r257", "r258", "r259" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r15", "r16", "r62", "r120", "r131", "r132", "r133", "r136", "r137", "r138", "r139", "r140", "r142", "r143", "r214", "r217", "r218", "r236", "r257", "r258" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Total Noncurrent Liabilities", "totalLabel": "Total Noncurrent Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r43" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized gain on marketable securities held in Trust Account" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Exercise price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Dividend yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Risk-free rate of interest" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Common stock price" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsFairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r101", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS [TEXT BLOCK]", "terseLabel": "ORGANIZATION AND PLANS OF BUSINESS OPERATIONS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "terseLabel": "Net cash provided by financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:", "terseLabel": "Cash Flows From Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r51", "r52", "r55" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:", "terseLabel": "Cash Flows used in Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r35", "r36", "r40", "r41", "r55", "r62", "r69", "r71", "r72", "r74", "r75", "r79", "r80", "r88", "r111", "r112", "r115", "r116", "r118", "r120", "r131", "r132", "r133", "r136", "r137", "r138", "r139", "r140", "r142", "r143", "r225", "r236", "r283", "r292" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r71", "r72", "r74", "r75", "r82", "r83", "r89", "r92", "r111", "r112", "r115", "r116", "r118" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Non-redeemable net income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r45" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income:", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r27", "r64", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Parties, Current", "verboseLabel": "Related party note payable" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r111", "r112", "r115", "r116", "r118" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND PLANS OF BUSINESS OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-allotment option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r49" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18", "r154" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value, (per share)", "verboseLabel": "Preferred stock, par value, (per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitPreferredStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred shares, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitPreferredStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18", "r154" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred shares, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitPreferredStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "verboseLabel": "Preferred shares, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitPreferredStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18", "r259" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 1,000,000 authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r25", "r124", "r125" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "verboseLabel": "Prepaid expenses - current" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r12" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense, Noncurrent", "terseLabel": "Prepaid expenses - noncurrent" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from issuance initial public offering.", "terseLabel": "Proceeds from issuance initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r46" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from the sale of Private Placements Warrants", "verboseLabel": "Aggregate purchase price" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r47" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "verboseLabel": "Proceeds from promissory note - related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r35", "r36", "r40", "r50", "r62", "r69", "r79", "r80", "r111", "r112", "r115", "r116", "r118", "r120", "r131", "r132", "r133", "r136", "r137", "r138", "r139", "r140", "r142", "r143", "r212", "r215", "r216", "r219", "r220", "r225", "r236", "r285" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss", "terseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r187", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r187", "r251", "r252", "r254" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r187", "r251", "r254", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r249", "r250", "r252", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r48" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Repayment of promissory note - related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r177", "r259", "r289", "r298", "r303" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r66", "r67", "r68", "r70", "r77", "r80", "r121", "r191", "r192", "r193", "r205", "r206", "r223", "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net income per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r71", "r72", "r73", "r76", "r77", "r79", "r80", "r95" ], "lang": { "en-us": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsCompanySCondensedStatementsOfCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r78", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule of effect of the restatement on each financial statement", "terseLabel": "Schedule of impact of the revision on financial statements" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRevisionOfPreviouslyIssuedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r17", "r18", "r19", "r60", "r98", "r99", "r150", "r152", "r153", "r154", "r155", "r156", "r157", "r159", "r163", "r168", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Issue price per unit.", "terseLabel": "Issue price per unit" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares": { "auth_ref": [ "r149" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares", "netLabel": "Warrant liability", "terseLabel": "Warrant liability", "verboseLabel": "Fair value of warrant liabilities" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r14", "r259", "r280", "r288" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-Term Debt", "terseLabel": "Working capital loan payable" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r17", "r18", "r19", "r60", "r62", "r85", "r86", "r87", "r90", "r92", "r98", "r99", "r100", "r120", "r131", "r136", "r137", "r138", "r142", "r143", "r154", "r155", "r159", "r163", "r170", "r236", "r310" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r34", "r38", "r39", "r40", "r66", "r67", "r68", "r70", "r77", "r80", "r97", "r121", "r170", "r177", "r191", "r192", "r193", "r205", "r206", "r223", "r238", "r239", "r240", "r241", "r242", "r243", "r248", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Cash Flows (unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Changes in Stockholders' Deficit (unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r66", "r67", "r68", "r97", "r266" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnauditedParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r170", "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Class B common stock to Sponsors (in shares)", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r170", "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Class B common stock to Sponsors", "verboseLabel": "Aggregate purchase price" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r22", "r23", "r62", "r119", "r120", "r236", "r259" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total Stockholders' Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' DEFICIT" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r61", "r155", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r169", "r177", "r179", "r221" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' DEFICIT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r260", "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "terseLabel": "Remeasurement on Class A common stock subject to possible redemption amount" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r131", "r136", "r137", "r138", "r142", "r143" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Class A common stock subject to possible redemption", "verboseLabel": "Class A Common stock subject to possible redemption, 31,050,000 shares at redemption value as of June 30, 2022 and December 31, 2021" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesClassCommonStockSubjectToPossibleRedemptionDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r33", "r62", "r120", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Net income (loss) attributable to Class A common stock subject to possible redemption" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares issued", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "terseLabel": "Class A common stock subject to possible redemption, issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares outstanding", "terseLabel": "Class A common stock subject to possible redemption, outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersDeficitCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of 31,050,000 Units" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r7", "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "terseLabel": "Schedule of reconciliation of Class A common stock subject to possible redemption" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r54" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedTerseLabel": "Unrealized gain on marketable securities held in Trust Account" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r194", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits accrued for interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r102", "r103", "r105", "r106", "r107", "r108", "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Public Warrants expiration term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r84", "r92" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of shares outstanding, Diluted", "verboseLabel": "Diluted weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r82", "r92" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares outstanding, Basic", "verboseLabel": "Basic weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r305": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r306": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r307": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r308": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r309": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r311": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r312": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" } }, "version": "2.1" } ZIP 57 0001104659-22-092128-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-092128-xbrl.zip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

  •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
  •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

  •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�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